Set Analyses:
Advanced Search

Advanced Search

Search By
Section (entire)


TP53 Gene

protein-coding   GIFtS: 80
GCID: GC17M007565

Tumor Protein P53

  See TP53-related diseases

(According to 1HGNC, 2Entrez Gene,
3UniProtKB/Swiss-Prot, 4UniProtKB/TrEMBL, 5OMIM, 6GeneLoc, 7Ensembl, 8DME, 9miRBase, 10fRNAdb, 12H-InvDB, 13NCBI, 14NONCODE, and/or 15RNAdb)
About This Section

Tumor Protein P531 2     TRP532
P532 3 5     Cellular Tumor Antigen P532
Antigen NY-CO-132 3     Mutant Tumor Protein 532
Phosphoprotein P532 3     P53 Tumor Suppressor2
BCC72 5     Transformation-Related Protein 532
LFS12 5     Tumor Protein 532
Li-Fraumeni Syndrome1     Tumor Suppressor P533

External Ids:    HGNC: 119981   Entrez Gene: 71572   Ensembl: ENSG000001415107   OMIM: 1911705   UniProtKB: P046373   

Export aliases for TP53 gene to outside databases

Previous GC identifiers: GC17P008026 GC17M008311 GC17M007514 GC17M007772 GC17M007512 GC17M007465

(According to Entrez Gene, GeneCards, Tocris Bioscience, Wikipedia's Gene Wiki, PharmGKB,
UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL)
About This Section

Entrez Gene summary for TP53 Gene:
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and
oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of
target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism.
Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as
Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple
transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate
translation initiation codons (PMIDs: 12032546, 20937277). (provided by RefSeq, Feb 2013)

GeneCards Summary for TP53 Gene:
TP53 (tumor protein p53) is a protein-coding gene. Diseases associated with TP53 include multifocal osteogenic sarcoma, and eyelid neoplasm. GO annotations related to this gene include protein heterodimerization activity and sequence-specific DNA binding transcription factor activity. An important paralog of this gene is TP73.

UniProtKB/Swiss-Prot: P53_HUMAN, P04637
Function: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the
physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to
negatively regulate cell division by controlling a set of genes required for this process. One of the activated
genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation
of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF
is involved in activating oxidative stress-induced necrosis; the function is largely independent of
transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1.
LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to
effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when
associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the
transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses
transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform
1-mediated apoptosis

summary for TP53 Gene:
p53 (aka TP53) is a transcription factor whose protein levels and post-translational modification state
alter in response to cellular stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins
through a number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs. MDM2 is a ubiquitn
ligase that binds p53 and targets p53 for proteasomal degradation. Phosphorylation, p14ARF and USP7 prevent
MDM2-p53 interactions, leading to an increase in stable p53 tetramers in the cytoplasm. Further
modifications such as methylation and acetylation lead to an increase in p53 binding to gene specific
response elements. p53 regulates a large number of genes (>100 genes) that control a number of key tumor
suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. Whilst the activation
of p53 often leads to apoptosis, p53 inactivation facilitates tumor progression; inactivating p53 mutations
occur in over 50% of cancers.

Gene Wiki entry for TP53 (P53) Gene

(According to GeneLoc and/or HGNC, and/or
Entrez Gene (NCBI build 37),
and/or miRBase,
Genomic Views according to UCSC (hg19) and Ensembl (release 75), Regulatory elements and Epigenetics data according to QIAGEN, and/or SwitchGear Genomics)
About This Section

RefSeq DNA sequence at NCBI GenBank:
NC_000017.10  NC_018928.2  NT_010718.17  
Regulatory elements:
   Regulatory transcription factor binding sites in the TP53 gene promoter:
         CREB   C/EBPbeta   Sp1   ARP-1   
         Other transcription factors

SwitchGear Promoter luciferase reporter plasmids (see all 4): TP53 promoter sequence
   Search Chromatin IP Primers for TP53

DNA Methylation CpG Assay Predesigned for Pyrosequencing in human, mouse, rat TP53

Genomic Location:
Genomic View: UCSC Golden Path with GeneCards custom track

Entrez Gene cytogenetic band: 17p13.1   Ensembl cytogenetic band:  17p13.1   HGNC cytogenetic band: 17p13.1

TP53 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)
TP53 gene location

GeneLoc information about chromosome 17         GeneLoc Exon Structure

GeneLoc location for GC17M007565:  view genomic region     (about GC identifiers)

7,565,097 bp from pter      End:
7,590,863 bp from pter
25,767 bases      Orientation:
minus strand
ORGUL member locations:
Legend (see complete legend)

ORGUL Member Locations for TP53

(According to 1UniProtKB, HORDE, 2neXtProt, Ensembl, and/or Reactome, Modification sites according to PhosphoSitePlus, Specific Peptides from DME, RefSeq according to NCBI, PDB rendering according to OCA and/or Proteopedia, Recombinant Proteins from EMD Millipore, R&D Systems, GenScript, Enzo Life Sciences, OriGene, Novus Biologicals, Sino Biological, ProSpec, Cloud-Clone Corp., eBioscience, antibodies-online, and/or GeneTex,
Biochemical Assays by EMD Millipore, R&D Systems, OriGene, GenScript, Cell Signaling Technology, Enzo Life Sciences, Cloud-Clone Corp., eBioscience, and/or antibodies-online, Antibodies by EMD Millipore, R&D Systems, Cell Signaling Technology, OriGene, Novus Biologicals, Thermo Fisher Scientific, Abcam, Cloud-Clone Corp, antibodies-online, and/or GeneTex.)
About This Section

UniProtKB/Swiss-Prot: P53_HUMAN, P04637 (See protein sequence)
Recommended Name: Cellular tumor antigen p53  
Size: 393 amino acids; 43653 Da
Cofactor: Binds 1 zinc ion per subunit
Subunit: Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity).
Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and
CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer-associated/HPV (E6) viral
proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This
complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6.
Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this
interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1.
Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1.
Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity).
Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction
enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts
(via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus).
Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with
FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the
phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation.
Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382)
with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK
complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with
AURKB, SETD2, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2.
Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the
association implicates preferentially tetrameric TP53, is induced by oxidative stress and is impaired by
cyclosporin A (CsA). Interacts with human cytomegalovirus/HHV-5 protein UL123. Interacts with SNAI1; the
interaction induces SNAI1 degradation via MDM2-mediated ubiquitination and inhibits SNAI1-induced cell invasion.
Interacts with KAT6A. Interacts with UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via
DNA-binding domain) with ZNF385A; the interaction is direct and enhances p53/TP53 transactivation functions on
cell-cycle arrest target genes, resulting in growth arrest. Interacts with ANKRD2. Interacts with RFFL (via
RING-type zinc finger); involved in p53/TP53 ubiquitination
Selected PDB 3D structures from and Proteopedia for TP53 (see all 119):
1A1U (3D)        1AIE (3D)        1C26 (3D)        1DT7 (3D)        1GZH (3D)        1H26 (3D)    
Secondary accessions: Q15086 Q15087 Q15088 Q16535 Q16807 Q16808 Q16809 Q16810 Q16811 Q16848
Q2XN98 Q3LRW1 Q3LRW2 Q3LRW3 Q3LRW4 Q3LRW5 Q86UG1 Q8J016 Q99659 Q9BTM4 Q9HAQ8 Q9NP68 Q9NPJ2
Alternative promoter usage, Alternative splicing: 9 isoforms:  P04637-1   P04637-2   P04637-3   P04637-4   P04637-5   P04637-6   P04637-7   P04637-8   
P04637-9   (Produced by alternative promoter usage and alternative splicing)

Explore the universe of human proteins at neXtProt for TP53: NX_P04637

Explore proteomics data for TP53 at MOPED

Post-translational modifications: 

  • Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1
    impairs its ability to induce proapoptotic program and modulate cell senescence1
  • Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity).
    Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by
    VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2.
    Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated
    apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33
    by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation.
    Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not
    gamma irradiation. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with
    BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was intially thought to be mediated by STK11/LKB1 but it was
    later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream
    NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on
    Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction
    in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in
    response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
    particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated by DYRK2
    at Ser-46 in response to genotoxic stress. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to
  • Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the
    AC form of PP2A1
  • May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line1
  • Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in
    cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not
    targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal
    degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24 and RFFL, which
    leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading
    to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner1
  • Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation.
    Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional
    regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at
    Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction
    with L3MBTL1 and leading to repress transcriptional activity. Dimethylation at Lys-370 and Lys-382 diminishes p53
    ubiquitination, through stabilizing association with the methyl reader PHF20. Demethylation of dimethylated
    Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation1
  • Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC91
  • Ubiquitination2 at Lys101, Lys132, Lys164, Lys291, Lys292, Lys305, Lys320, Lys321
  • Modification sites at PhosphoSitePlus

  • See TP53 Protein Expression from SPIRE MOPED, PaxDB, and MaxQB

    REFSEQ proteins (15 alternative transcripts): 
    NP_000537.3  NP_001119584.1  NP_001119585.1  NP_001119586.1  NP_001119587.1  NP_001119588.1  NP_001119589.1  NP_001119590.1  
    NP_001263624.1  NP_001263625.1  NP_001263626.1  NP_001263627.1  NP_001263628.1  NP_001263689.1  NP_001263690.1  

    ENSEMBL proteins: 
     ENSP00000410739   ENSP00000352610   ENSP00000269305   ENSP00000398846   ENSP00000391127  
     ENSP00000391478   ENSP00000458393   ENSP00000425104   ENSP00000423862   ENSP00000424104  
     ENSP00000473895   ENSP00000426252  
    Reactome Protein details: P04637

    TP53 Human Recombinant Protein Products:

    EMD Millipore Purified and/or Recombinant TP53 Protein
    R&D Systems Recombinant & Natural Proteins for TP53 (p53)
    Enzo Life Sciences proteins for TP53
    OriGene Purified Proteins for TP53
    OriGene Protein Over-expression Lysate for TP53
    OriGene MassSpec for TP53
    OriGene Custom Protein Services for TP53
    GenScript Custom Purified and Recombinant Proteins Services for TP53
    Novus Biologicals TP53 Proteins
    Novus Biologicals TP53 Lysates
    Sino Biological Recombinant Protein for TP53
    Browse Sino Biological Cell Lysates
    ProSpec Recombinant Protein for TP53
    Cloud-Clone Corp. Proteins for TP53

    Search eBioscience for Proteins for TP53 

    antibodies-online proteins for TP53 (61 products) 

    antibodies-online peptides for TP53

    Search GeneTex for Proteins for TP53 

    TP53 Antibody Products:

    EMD Millipore Mono- and Polyclonal Antibodies for the study of TP53
    R&D Systems Antibodies for TP53 (p53)
    Cell Signaling Technology (CST) Antibodies for TP53  (p53)
    OriGene Antibodies for TP53
    OriGene Custom Antibody Services for TP53
    Novus Biologicals TP53 Antibodies
    Abcam antibodies for TP53
    Cloud-Clone Corp. Antibodies for TP53
    ThermoFisher Antibody for TP53
    antibodies-online antibodies for TP53 (1437 products) 

    GeneTex Antibodies for TP53:  
                        TP53 Antibodies

    TP53 Assay Products:

    EMD Millipore Kits and Assays for the Analysis of TP53
    OriGene Custom Assay Services for TP53
    R&D Systems ELISAs for TP53 (p53)         (see first)
    R&D Systems Ubiquitin Proteasome Pathway (UPP) Assay Kits & Reagents for TP53 (p53)
    R&D Systems Proteome Profiler Antibody Arrays for TP53 (p53)
    See all other biochemical assays at R&D Systems
    GenScript Custom Assay Services for TP53
    Cell Signaling Technology (CST) Sandwich ELISA Kits for TP53 (p53)
    Enzo Life Sciences assays for TP53
    Cloud-Clone Corp. ELISAs for TP53
    Cloud-Clone Corp. CLIAs for TP53
    eBioscience ELISAs for TP53: (see all 4
                        p53 (Total/Phospho) InstantOne ELISA 96 tests
    antibodies-online kits for TP53 (80 products) 

    (According to HGNC, IUPHAR, InterPro, ProtoNet, UniProtKB, and/or BLOCKS, Sets of similar genes according to GenesLikeMe)
    About This Section

    Selected InterPro protein domains (see all 6):
     IPR011615 p53_DNA-bd
     IPR012346 p53/RUNT-type_TF_DNA-bd
     IPR002117 p53_tumour_suppressor
     IPR008967 p53-like_TF_DNA-bd
     IPR013872 p53_transactivation_domain

    Graphical View of Domain Structure for InterPro Entry P04637

    ProtoNet protein and cluster: P04637

    1 Blocks protein domain: IPB010991 p53

    UniProtKB/Swiss-Prot: P53_HUMAN, P04637
    Domain: The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues
    17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large
    number of yeast and animal transcription factors
    Similarity: Belongs to the p53 family

    Find genes that share domains with TP53           About GenesLikeMe

    (According to 1UniProtKB, Genatlas, LifeMap Discovery™, IUBMB, and/or 2DME, Human phenotypes from GenomeRNAi, Animal models from MGI Mar 06 2013, genOway, and/or Taconic Biosciences, CRISPR knockouts from OriGene, transcription factor targeting from QIAGEN and/or HOMER, miRNA Gene Targets from miRTarBase, shRNA from OriGene, siRNAs from OriGene, QIAGEN, microRNA from QIAGEN, SwitchGear Genomics, Clones from OriGene, GenScript, Sino Biological, Vector BioLabs and/or Addgene, Cell Lines from GenScript, ESI BIO, In Situ Hybridization Assays from Advanced Cell Diagnostics, Flow cytometry from eBioscience, Ontologies according to Gene Ontology Consortium 01 Apr 2014 via Entrez Gene, Sets of similar genes according to GenesLikeMe)
    About This Section

    Molecular Function:

         UniProtKB/Swiss-Prot Summary: P53_HUMAN, P04637
    Function: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the
    physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to
    negatively regulate cell division by controlling a set of genes required for this process. One of the activated
    genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation
    of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF
    is involved in activating oxidative stress-induced necrosis; the function is largely independent of
    transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1.
    LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to
    effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when
    associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the
    transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses
    transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform
    1-mediated apoptosis
    Induction: Up-regulated in response to DNA damage. Isoform 2 is not induced in tumor cells in response to stress

         Genatlas biochemistry entry for TP53:
    tumor suppressor protein p53 required for G1 growth arrest by WAF1 (CDKN1A),following DNA damage or induction of
    apoptosis,also regulating a G2 checkpoint through cyclin B1,transcriptional activator through acetylation of
    transactivation site by CREBBP binding MDM2 resulting in transcriptional silencing and ubiquitin/proteasome
    dependent degradation of p53,activated by conjugation to UBL1 (SUMO1),putative up-regulated c-MYC target
    gene,putative teratologic suppressor gene and modulator of TFIIH (GTF2H),associated in nucleotide excision
    repair,activated by ATM in association with 14.3.3 proteins (YWHA*),tumor suppressor gene (see TSG17A),mutated in
    cancers such as pancreas and endometrial carcinomas,in Barrett's adenocarcinoma (and esophageal squamous cell
    carcinoma),in hepatocellular carcinoma with poor prognosis

         Gene Ontology (GO): Selected molecular function terms (see all 30):    About this table

    GO IDQualified GO termEvidencePubMed IDs
    GO:0000979RNA polymerase II core promoter sequence-specific DNA binding IEA--
    GO:0001077RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription IEA--
    GO:0001085RNA polymerase II transcription factor binding IPI18549481
    GO:0001228RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription IDA17146433
    GO:0002020protease binding IPI11923872
    Find genes that share ontologies with TP53           About GenesLikeMe

         4 GenomeRNAi human phenotypes for TP53:
     Decreased viability of wild-ty  Enable proliferation in B-Raf   Increased cell death HMECs cel  Increased resistance to MDM2 i 

         Selected MGI mutant phenotypes (inferred from 73 alleles(MGI details for Trp53) (see all 27):
     adipose tissue  behavior/neurological  cardiovascular system  cellular  craniofacial 
     digestive/alimentary  embryogenesis  endocrine/exocrine gland  growth/size/body  hematopoietic system 
     homeostasis/metabolism  immune system  integument  limbs/digits/tail  liver/biliary system 

    Find genes that share phenotypes with TP53           About GenesLikeMe

    Animal Models:
         MGI mouse knock-outs for TP53: Trp53tm1Mlh Trp53tm3Wahl Trp53tm5Wahl Trp53tm2Wahl Trp53tm1.1Manf Trp53tm1Tyj
                                                         Trp53tm1Mok Trp53tm1Sia Trp53tm1.1Brn Trp53tm1Brd

       genOway: Develop your customized and physiologically relevant rodent model for TP53

        Taconic Biosicences: Generate A Custom CRISPR Mouse Model For Your Study 

    CRISPR Knockouts: 
       OriGene CRISPR knockouts for TP53

    Transcription Factor Targeting: 

    Selected GeneGlobe predicted Target genes for TP53 (see all 1892):
    AATF,  ABCC3,  ABCC6P2,  ABCD1,  ABCF1,  ABHD12,  ABHD15,  ABHD4,  ABHD8,  ABTB2

    Targeting motifs: HOMER Transcription Factor Regulatory Elements motif viewer 
                                          Consensus sequence:  AACATGCCCAGACATGCCCN 

    miRTarBase miRNAs that target TP53:
    hsa-mir-1285-3p (MIRT005474), hsa-mir-125a-5p (MIRT004071), hsa-mir-221-3p (MIRT005785), hsa-mir-10b-5p (MIRT006923), hsa-mir-608 (MIRT016154), hsa-mir-324-5p (MIRT043041), hsa-mir-30d-5p (MIRT005418), hsa-mir-454-3p (MIRT039245), hsa-mir-16-5p (MIRT005764), hsa-mir-25-3p (MIRT005417), hsa-mir-15a-5p (MIRT005763), hsa-mir-605-5p (MIRT016155), hsa-mir-27a-3p (MIRT028744), hsa-mir-214-3p (MIRT006881), hsa-mir-34a-5p (MIRT007112), hsa-mir-150-5p (MIRT052652), hsa-mir-485-5p (MIRT016616), hsa-mir-222-3p (MIRT005786), hsa-mir-612 (MIRT005476), hsa-mir-504-5p (MIRT016257), hsa-mir-125b-5p (MIRT000535)

    Block miRNA regulation of human, mouse, rat TP53 using miScript Target Protectors
    Selected qRT-PCR Assays for microRNAs that regulate TP53 (see all 17):
    hsa-miR-576-3p hsa-let-7d hsa-miR-202 hsa-let-7c hsa-let-7g hsa-let-7a hsa-miR-98 hsa-miR-22
    SwitchGear 3'UTR luciferase reporter plasmidTP53 3' UTR sequence
    Inhib. RNA
    OriGene RNAi products in human, mouse, rat for TP53
    Predesigned siRNA for gene silencing in human, mouse, rat TP53

    OriGene clones in human, mouse for TP53 (see all 37)
    OriGene ORF clones in mouse, rat for TP53
    OriGene custom cloning services - gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
    GenScript: all cDNA clones in your preferred vector (see all 7): TP53 (NM_000546)
    Sino Biological Human cDNA Clone for TP53
    Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat TP53
    Addgene plasmids for TP53 

    Cell Line
    GenScript Custom overexpressing Cell Line Services for TP53
    Browse ESI BIO Cell Lines and PureStem Progenitors for TP53 
    In Situ Assay

    Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for TP53

    Flow Cytometry

    eBioscience FlowRNA Probe Sets ( VA1-11152 VA6-13337) for TP53 

    (According to UniProtKB, COMPARTMENTS Subcellular localization database, Ontologies according to Gene Ontology Consortium 01 Apr 2014 via Entrez Gene, Sets of similar genes according to GenesLikeMe)
    About This Section

    Subcellular locations from UniProtKB/Swiss-Prot
    P53_HUMAN, P04637: Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix.
    Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2.
    Translocates to mitochondria upon oxidative stress
    P53_HUMAN, P04637: Isoform 1: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm
    when expressed with isoform 4
    P53_HUMAN, P04637: Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in
    the cytoplasm
    P53_HUMAN, P04637: Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the
    cytoplasm in some cells
    P53_HUMAN, P04637: Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm
    following cell stress
    P53_HUMAN, P04637: Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in
    the cytoplasm
    P53_HUMAN, P04637: Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells.
    In some cells, forms foci in the nucleus that are different from nucleoli
    P53_HUMAN, P04637: Isoform 9: Cytoplasm
    Subcellular locations from COMPARTMENTS: 

    endoplasmic reticulum5
    plasma membrane2
    golgi apparatus1

    Gene Ontology (GO): Selected cellular component terms (see all 16):    About this table

    GO IDQualified GO termEvidencePubMed IDs
    GO:0000785chromatin IBA--
    GO:0000790nuclear chromatin IDA15710329
    GO:0005634nucleus IDA--
    GO:0005654nucleoplasm TAS--
    GO:0005657replication fork IBA--

    Find genes that share ontologies with TP53           About GenesLikeMe

    (SuperPaths according to PathCards, Pathways according to R&D Systems, Cell Signaling Technology, KEGG, PharmGKB, BioSystems, Sino Biological, Reactome, Tocris Bioscience, GeneGo (Thomson Reuters), QIAGEN, and/or UniProtKB, Sets of similar genes according to GenesLikeMe, Interaction Networks according to QIAGEN, and/or STRING, Interactions according to 1UniProtKB, 2MINT, 3I2D, and/or 4STRING, with links to IntAct and Ensembl, Ontologies according to Gene Ontology Consortium 01 Apr 2014 via Entrez Gene, Sets of similar genes according to GenesLikeMe)
    About This Section

    SuperPaths for TP53 About   (see all 112)  
    See pathways by source

    SuperPathContained pathways About
    1Amyotrophic lateral sclerosis (ALS)
    Amyotrophic lateral sclerosis (ALS)0.63
    Pathogenesis of ALS0.31
    Amyotrophic lateral sclerosis (ALS)0.63
    Prostate cancer0.39
    Non-small cell lung cancer0.51
    Signaling Pathways in Glioblastoma0.36
    Bladder cancer0.31
    3Endometrial cancer
    Endometrial cancer0.45
    Colorectal cancer0.42
    Signal transduction PTEN pathway0.45
    4Development HGF signaling pathway
    Development Neurotrophin family signaling0.44
    Neurotrophin signaling pathway0.36
    Apoptosis and survival Role of CDK5 in neuronal death and survival0.37
    5Pyrimidine metabolism
    Fluoropyrimidine Activity0.69
    Fluoropyrimidine Pathway, Pharmacodynamics0.00

    Find genes that share SuperPaths with TP53           About GenesLikeMe

    Pathways by source                                   See SuperPaths
    Show all pathways

    2 R&D Systems Pathways for TP53
        Apoptosis Signaling Pathways
    Akt Signaling Pathway

    Selected Downloadable PowerPoint Slides of GeneGlobe Pathway Central Maps for TP53 (see all 41)
        Telomerase Components in Cell Signaling
    UVB-Induced MAPK Signaling
    Mitochondrial Apoptosis
    Molecular Mechanisms of Cancer
    TRKA Signaling

    2 Cell Signaling Technology (CST) Pathways for TP53
        Cell Cycle / Checkpoint Control
    DNA Damage

    4 Tocris Bioscience Pathways for TP53
        Akt Pathway
    Apoptosis Pathway
    MAPK Pathway
    mTOR Pathway

    Selected GeneGo (Thomson Reuters) Pathways for TP53 (see all 13)
        DNA damage ATM/ATR regulation of G1/S checkpoint
    Immune response MIF in innate immunity response
    Transcription P53 signaling pathway
    Development Neurotrophin family signaling
    Signal transduction AKT signaling

    Selected BioSystems Pathways for TP53 (see all 38)
        MAPK signaling pathway
    Cell cycle
    Fluoropyrimidine Activity
    DNA damage response

    3 Sino Biological Pathways for TP53
        EGFR Signaling Pathway
    p53 Pathway
    Death Receptor Signaling

    Selected Reactome Pathways for TP53 (see all 11)
        Stabilization of p53
    Transcriptional activation of cell cycle inhibitor p21
    Oncogene Induced Senescence
    Activation of NOXA and translocation to mitochondria
    Activation of PUMA and translocation to mitochondria

    2 PharmGKB Pathways for TP53
        Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
    Fluoropyrimidine Pathway, Pharmacodynamics

    Selected Kegg Pathways  (Kegg details for TP53) (see all 33):
        MAPK signaling pathway
    Cell cycle
    p53 signaling pathway
    PI3K-Akt signaling pathway

        Pathway & Disease-focused RT2 Profiler PCR Arrays including TP53 (see all 37): 
              Lung Cancer in human mouse rat
              Lymphoma in human mouse rat
              Prostate Cancer in human mouse rat
              Hypoxia Signaling Pathway in human mouse rat
              Stress & Toxicity PathwayFinder in human mouse rat


        GeneGlobe Interaction Network for TP53

    STRING Interaction Network Preview (showing 5 interactants - click image to see 25)

    Selected Interacting proteins for TP53 (P046371, 2, 3 ENSP000002693054) via UniProtKB, MINT, STRING, and/or I2D (see all 951)
    InteractantInteraction Details
    GeneCardExternal ID(s)
    MDM2Q009871, 2, 3, ENSP000004172814EBI-366083,EBI-389668 MINT-6540920 MINT-4793511 MINT-6823775 MINT-7013943 MINT-8303857 MINT-6540905 MINT-68742 MINT-8385459 MINT-56681 MINT-8374464 MINT-58468 MINT-7013791 MINT-68743 MINT-7013956 MINT-4545014 MINT-8339574 MINT-4049631 MINT-6540776 MINT-6801380 MINT-8374452 MINT-58465 MINT-7013688 MINT-7013802 MINT-4303990 MINT-8339590 MINT-6665330 MINT-4793467 MINT-8380636 MINT-4049616 MINT-4054304 MINT-7905142 MINT-8385480 MINT-7013780 MINT-6540889 MINT-8385531 MINT-8385552 MINT-8385886 MINT-8388795 MINT-8415355 MINT-6540807 MINT-8391984 MINT-7905326 MINT-6540796 I2D: score=12 STRING: ENSP00000417281
    OTUB1Q96FW11, 2, 3EBI-366083,EBI-1058491 MINT-8380020 MINT-8380061 MINT-8380636 MINT-8380008 MINT-8380032 MINT-8388795 MINT-8380053 MINT-8388765 I2D: score=1 
    HNRNPUL1Q9BUJ22, 3, ENSP000003758634MINT-58678 MINT-58677 MINT-58673 MINT-58674 MINT-58676 MINT-58675 MINT-8415355 MINT-58672 I2D: score=3 STRING: ENSP00000375863
    UBCP0CG481, 2, 3, ENSP000003448184EBI-366083,EBI-3390054 MINT-7220023 MINT-4051326 MINT-4304004 MINT-4054804 MINT-4304143 MINT-6801380 MINT-6615153 MINT-6541035 MINT-7299234 MINT-7298704 MINT-6799774 MINT-7013815 MINT-4052207 MINT-7219995 MINT-5114741 I2D: score=5 STRING: ENSP00000344818
    PSME3P612891, 2, 3, ENSP000002933624EBI-366083,EBI-355546 MINT-6540807 MINT-6540940 MINT-6540866 MINT-6540920 MINT-6540876 MINT-6540776 MINT-6541016 MINT-6540960 MINT-6540796 I2D: score=3 STRING: ENSP00000293362
    About this table

    Gene Ontology (GO): Selected biological process terms (see all 102):    About this table

    GO IDQualified GO termEvidencePubMed IDs
    GO:0000060protein import into nucleus, translocation IEA--
    GO:0000122negative regulation of transcription from RNA polymerase II promoter ISS19749791
    GO:0000733DNA strand renaturation IDA8183576
    GO:0001701in utero embryonic development IEA--
    GO:0001756somitogenesis IEA--

    Find genes that share ontologies with TP53           About GenesLikeMe

    (Chemical Compounds according to UniProtKB, Enzo Life Sciences, EMD Millipore, Tocris Bioscience, ApexBio, HMDB, BitterDB, and/or Novoseek, Ligands according to IUPHAR, and Drugs according to DrugBank, Enzo Life Sciences, and/or PharmGKB, Sets of similar genes according to GenesLikeMe)
    About This Section

    Browse Small Molecules at EMD Millipore
       Enzo Life Sciences drugs & compounds for TP53
    Selected ApexBio Compounds for TP53 (see all 15)     About this table
    CompoundAction CAS #
    AMG232potent and selective piperidinone inhibitor of the MDM2-p53 interaction--
    CP 31398 dihydrochloridep53 stabilizing agent. [1217195-61-3]
    JNJ-26854165 (Serdemetan)p53 activator, blocking Mdm2-p53 interaction[881202-45-5]
    Nutlin-3inhibitor of the MDM2/p53 interaction[890090-75-2]
    Nutlin-3a chiralinhibits the MDM2-p53 interaction and activates p53. [675576-98-4]
    p53 and MDM2 proteins-interaction-inhibitor chiralinhibitor of the interaction between p53 and MDM2 proteins[939981-37-0]
    Pifithrin-miuInhibits p53 binding to mitochondria[64984-31-2]
    PRIMA-1Cell-permeable BAX inhibitor, restore p53 activity[5608-24-2]
    PRIMA-1METCell-permeable BAX inhibitor, restore p53 activity[5291-32-7]
    RG7112Restoration of p53 activity by inhibiting the p53-MDM2 interaction[939981-39-2]

    Compounds for TP53 available from Tocris Bioscience    About this table
    CompoundAction CAS #
    PRIMA-1METRestores mutant p53 activity[5291-32-7]
    Pifithrin-alpha hydrobromidep53 inhibitor. Also aryl hydrocarbon receptor agonist[63208-82-2]
    RITAMDM2-p53 interaction inhibitor[213261-59-7]
    Cyclic Pifithrin-alpha hydrobromidep53 inhibitor[511296-88-1]
    Pifithrin-muInhibitor of p53-mitochondrial binding[64984-31-2]

    1 DrugBank Compound for TP53    About this table
    CompoundSynonyms CAS #TypeActionsPubMed Ids
    1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine-- --target--10592235

    Selected Novoseek inferred chemical compound relationships for TP53 gene (see all 117)    About this table
    Compound   -log (P-Val)   Hits   PubMed IDs for Articles with Shared Sentences (# sentences)
    paraffin 76.9 382 8640471 (4), 7726729 (4), 8434637 (4), 15363320 (4) (see all 99)
    cisplatin 74 1151 12492119 (9), 9811465 (8), 18064040 (7), 14513366 (7) (see all 99)
    noxa 72.7 89 17216584 (4), 17653088 (3), 20160496 (3), 15598651 (3) (see all 52)
    hpvs 71.4 72 20200430 (2), 11002226 (2), 8726818 (2), 9714244 (1) (see all 50)
    estrogen 71 898 14595509 (6), 9744308 (5), 10719737 (4), 15312749 (4) (see all 99)
    progesterone 69.1 712 12416559 (6), 14595509 (5), 9635673 (5), 9744308 (5) (see all 99)
    doxorubicin 67.6 464 15116093 (6), 18263706 (6), 8988061 (5), 11745235 (5) (see all 99)
    aflatoxin b1 63.4 212 16280384 (6), 8921985 (5), 19524575 (5), 1310637 (5) (see all 90)
    5fluorouracil 63.2 456 17634554 (12), 11044365 (7), 14703431 (7), 19810096 (6) (see all 99)
    camptothecin 63.1 172 10536167 (6), 9815856 (5), 19445707 (4), 17709397 (3) (see all 75)

    5 PharmGKB related drug/compound annotations for TP53 gene    About this table
    Drug/compound PharmGKB Annotation
    antineoplastic agentsCA  

    Find genes that share compounds with TP53           About GenesLikeMe

    (Secondary structures according to fRNAdb,
    GenBank/EMBL/DDBJ Accessions according to
    Unigene (Build 236 Homo sapiens; Apr 25 2013) or GenBank,
    RefSeq according to Entrez Gene,
    DOTS (version 10), and/or AceView, transcript ids from Ensembl with links to UCSC,
    exon structure from GeneLoc, alternative splicing isoforms according to ASD and/or ECgene,
    siRNAs from OriGene, QIAGEN, shRNA from OriGene, microRNA from QIAGEN, SwitchGear Genomics,
    Tagged/untagged cDNA clones from OriGene, GenScript, Vector BioLabs, and/or Addgene, Primers from OriGene, and/or QIAGEN, Flow cytometry from eBioscience )
    About This Section

    REFSEQ mRNAs for TP53 gene (15 alternative transcripts): 
    NM_000546.5  NM_001126112.2  NM_001126113.2  NM_001126114.2  NM_001126115.1  NM_001126116.1  NM_001126117.1  NM_001126118.1  
    NM_001276695.1  NM_001276696.1  NM_001276697.1  NM_001276698.1  NM_001276699.1  NM_001276760.1  NM_001276761.1  

    Unigene Cluster for TP53:

    Tumor protein p53
    Hs.437460  [show with all ESTs]
    Unigene Representative Sequence: NM_001126114
    17 Ensembl transcripts including schematic representations, and UCSC links where relevant:
    ENST00000413465(uc002gig.1) ENST00000359597(uc002gih.3) ENST00000504290(uc010cnf.1)
    ENST00000510385(uc010cng.1) ENST00000504937(uc010cne.1 uc002gii.1)
    ENST00000269305(uc002gim.2 uc002gij.2 uc002gin.2 uc002gio.2 uc010cnk.1)
    ENST00000455263(uc010cnh.1) ENST00000420246(uc010cni.1) ENST00000445888
    ENST00000576024 ENST00000509690(uc010cnj.1) ENST00000514944 ENST00000574684
    ENST00000505014(uc010vug.2) ENST00000508793 ENST00000604348 ENST00000503591

    Block miRNA regulation of human, mouse, rat TP53 using miScript Target Protectors
    Selected qRT-PCR Assays for microRNAs that regulate TP53 (see all 17):
    hsa-miR-576-3p hsa-let-7d hsa-miR-202 hsa-let-7c hsa-let-7g hsa-let-7a hsa-miR-98 hsa-miR-22
    SwitchGear 3'UTR luciferase reporter plasmidTP53 3' UTR sequence
    Inhib. RNA
    OriGene RNAi products in human, mouse, rat for TP53
    Predesigned siRNA for gene silencing in human, mouse, rat TP53
    OriGene clones in human, mouse for TP53 (see all 37)
    OriGene ORF clones in mouse, rat for TP53
    OriGene custom cloning services - gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
    GenScript: all cDNA clones in your preferred vector (see all 7): TP53 (NM_000546)
    Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat TP53
    Addgene plasmids for TP53 
    OriGene qPCR primer pairs and template standards for TP53
    OriGene qSTAR qPCR primer pairs in human, mouse for TP53
    Pre-validated RT2 qPCR Primer Assay in human, mouse, rat TP53
      QuantiTect SYBR Green Assays in human, mouse, rat TP53
      Search QuantiFast Probe-based Assays in human, mouse, rat TP53
    Flow Cytometry

    eBioscience FlowRNA Probe Sets ( VA1-11152 VA6-13337) for TP53 

    Additional mRNA sequence: 

    AB082923.1 AF052180.1 AF307851.1 AK223026.1 AK225838.1 AK297462.1 AK297927.1 AK312568.1 
    AM076970.1 AM076971.1 AM076972.1 AY429684.1 BC003596.1 BT019622.1 DQ186648.1 DQ186649.1 
    DQ186650.1 DQ186651.1 DQ186652.1 DQ191317.1 DQ263704.1 DQ286964.1 DQ401704.1 DQ485152.1 
    DQ648884.1 DQ648885.1 DQ648886.1 DQ648887.1 EF101867.1 EF101868.1 EF101869.1 FJ207420.1 
    JN900492.1 M14694.1 M14695.1 S66666.1 X01405.1 X02469.1 X60010.1 X60011.1 
    X60012.1 X60013.1 X60014.1 X60015.1 X60016.1 X60017.1 X60018.1 X60019.1 

    16 DOTS entries:

    DT.92469229  DT.100788714  DT.120961435  DT.100788713  DT.40283865  DT.75152217  DT.95274968  DT.100712946 
    DT.120961349  DT.40120491  DT.100788719  DT.120961395  DT.92010563  DT.100788715  DT.120961350  DT.120961391 

    Selected AceView cDNA sequences (see all 112):

    AY627884 X02469 BU174921 CK904490 AA662570 X60018 BX952582 AW865736 
    CR624912 X60012 CA432254 BQ057682 CR608294 AA291539 AA379547 BU673953 
    S66666 BQ066009 AI539544 BE886147 X60016 AA358870 X60017 BE300855 

    GeneLoc Exon Structure

    Selected Alternative Splicing Database (ASD) splice patterns (SP) for TP53 (see all 9)    About this scheme

    ExUns: 1a · 1b ^ 2 ^ 3 ^ 4 ^ 5a · 5b ^ 6 ^ 7 ^ 8 ^ 9a · 9b ^ 10a · 10b ^ 11 ^ 12a · 12b · 12c
    SP1:                                -                             -           -     -                           
    SP2:                                                              -                                             
    SP3:                                                              -           -                                 
    SP4:                                                              -           -     -                           
    SP5:                                                                          -     -                           

    ECgene alternative splicing isoforms for TP53

    (RNA expression data according to H-InvDB, NONCODE, miRBase, and RNAdb, Expression images according to data from BioGPS, Illumina Human BodyMap, and CGAP SAGE, Sets of similar genes according to GenesLikeMe, in vivo and in vitro expression data from LifeMap Discovery™, Protein expression images according to data from SPIRE 1MOPED, 2PaxDb, and 3MaxQB, plus additional links to SOURCE, and/or BioGPS, and/or UniProtKB,
    PCR Arrays from QIAGEN, Primers from OriGene, and/or QIAGEN, In Situ Hybridization Assays from Advanced Cell Diagnostics)
    About This Section

    TP53 expression in normal human tissues (normalized intensities)
    See probesets specificity/sensitivity at GeneAnnot
    About this imageBioGPS <intensity>2/3
    TP53 Expression
    About this image

    TP53 expression in embryonic tissues and stem cells    About this table
    Data from LifeMap, the Embryonic Development and Stem Cells Database
     selected tissues (see all 9) fully expand
     Endothelium (Cardiovascular System)    fully expand to see all 2 entries
             Peripheral blood-derived endothelial progenitor cells
     Thymus (Hematopoietic System)
             Double Negative 2 Thymocytes Thymus
     Neural Crest (Gastrulation Derivatives)
             Cranial Neural Crest Cells Cranial Neural Crest
     Inner Cell Mass (Early Embryonic Tissues)
     Kidney (Urinary System)
    TP53 Protein expression data from MOPED1, PaxDb2 and MaxQB3    About this image

    TP53 Protein Expression

    SOURCE GeneReport for Unigene cluster: Hs.437460

    UniProtKB/Swiss-Prot: P53_HUMAN, P04637
    Tissue specificity: Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent
    manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal
    brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung,
    spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is
    not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow,
    testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain,
    heart, lung, fetal liver, salivary gland, breast or intestine

        Pathway & Disease-focused RT2 Profiler PCR Arrays including TP53 (see all 37): 
              Lung Cancer in human mouse rat
              Lymphoma in human mouse rat
              Prostate Cancer in human mouse rat
              Hypoxia Signaling Pathway in human mouse rat
              Stress & Toxicity PathwayFinder in human mouse rat

    OriGene qPCR primer pairs and template standards for TP53
    OriGene qSTAR qPCR primer pairs in human, mouse for TP53
    Pre-validated RT2 qPCR Primer Assay in human, mouse, rat TP53
    QuantiTect SYBR Green Assays in human, mouse, rat TP53
    Search QuantiFast Probe-based Assays in human, mouse, rat TP53
    In Situ
    Assay Products:

    Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for TP53

    (Orthologs according to 1,2HomoloGene (2older version, for species not in 1newer version), 3euGenes, 4SGD , 5MGI Mar 06 2013, with possible further links to Flybase and/or WormBase, and/or 6Ensembl pan taxonomic compara , Gene Trees according to Ensembl and TreeFam)
    About This Section

    This gene was present in the common ancestor of chordates.

    Orthologs for TP53 gene from Selected species (see all 12)    About this table
    Organism Taxonomic
    Gene Description Human
    (Mus musculus)
    Mammalia Trp531 , 5 transformation related protein 531, 5 80.62(n)1
      11 (42.83 cM)5
    220591  NM_011640.31  NP_035770.21 
    (Anolis carolinensis)
    Reptilia --
    many ↔ many
    African clawed frog
    (Xenopus laevis)
    Amphibia Xl.209432 Xenopus laevis transcribed sequence with weak similarity more 78.01(n)    BU152764.1 
    (Danio rerio)
    Actinopterygii tp532 tumor protein p53 74.13(n)   30590  AF365873.1 

    ENSEMBL Gene Tree for TP53 (if available)
    TreeFam Gene Tree for TP53 (if available)

    (Paralogs according to 1HomoloGene,
    2Ensembl, and 3SIMAP, Pseudogenes according to Build 68,Sets of similar genes according to GenesLikeMe)
    About This Section

    Paralogs for TP53 gene
    TP732  TP632  
    3 SIMAP similar genes for TP53 using alignment to 109 protein entries:     P53_HUMAN (see all proteins):
    p53    TP63    TP73

    Find genes that share paralogs with TP53           About GenesLikeMe

    (SNPs/Variants according to the 1NCBI SNP Database, 2Ensembl, 3PupaSUITE, and 4UniProtKB, Linkage Disequilibrium by HapMap, Structural Variations(CNVs/InDels/Inversions) from the Database of Genomic Variants, Mutations from the Human Gene Mutation Database (HGMD), the Human Cytochrome P450 Allele Nomenclature Database, and the Locus Specific Mutation Databases (LSDB), Blood group antigen gene mutations by BGMUT, Resequencing Primers, Cancer Mutation PCR Arrays and Assays, and Copy Number PCR Arrays from QIAGEN)
    About This Section

    Selected SNPs for TP53 (see all 2063)    About this table                                 

    Genomic DataTranscription Related DataAllele Frequencies
    SNP IDValidClinical
    Chr 17 posSequence#AA
    CA familial cancer not matching LFS4 --7563133(-) CTCACT/GCCAGG 22 /A /S ut31 mis1 ese33Minor allele frequency- G:0.01NS NA 184
    C,F,HA sporadic cancer4 --7563214(-) GCTTCG/AAGATG 22 /K /E ut31 mis17Minor allele frequency- A:0.01NS EA NA 674
    CLi-Fraumeni syndrome (LFS)4 --7566271(+) TCTTGC/TGGAGA 30 H R mis10--------
    CLi-Fraumeni syndrome (LFS)4 pathogenic17566296(-) GAGACC/TGGCGC 30 R W mis1 ese30--------
    CLi-Fraumeni syndrome (LFS)4 pathogenic17566322(-) GGTGCA/GTGTTT 30 H R mis1 ese30--------
    CLi-Fraumeni syndrome (LFS)4 pathogenic17566713(-) CACACA/TGGAAG 30 Q L mis1 ese30--------
    CSporadic cancers4 other17566736(-) CGGAGG/TCCCAT 30 R S mis1 ese30--------
    CLi-Fraumeni syndrome (LFS)4 pathogenic17566740(-) GAACCA/GGAGGC 30 Q R mis1 ese30--------
    CLi-Fraumeni syndrome (LFS)4 pathogenic17566750(-) TGGGCA/G/TGCATG 45 S G C mis1 ese30--------
    CLi-Fraumeni syndrome (LFS)4 pathogenic17566761(-) CAGTTC/TCTGCA 30 S F mis1 ese30--------

    HapMap Linkage Disequilibrium report for TP53 (7565097 - 7590863 bp)

    Structural Variations
         Database of Genomic Variants (DGV) 1 variation for TP53:    About this table    
    Variant IDTypeSubtypePubMed ID
    nsv457659CNV Loss19166990

    Human Gene Mutation Database (HGMD): TP53
    Locus Specific Mutation Databases (LSDB): TP53

    Selected Site Specific Mutation Identification with PCR Assays for TP53 (see all 120):
    Cosmic IdAA Change
    Selected Site Specific Cancer Mutation PCR Panels containing TP53 (see all 22):
    Breast Cancer
    Cancer Comprehensive Panel 384HT
    Lung Cancer
    Myelodysplastic Syndromes
    Soft Tissue Tumors
    2 Copy Number PCR Panels containing TP53:
    Oncogenes & Tumor Suppressor Genes 384HC
    WNT Signaling
    SeqTarget long-range PCR primers for resequencing TP53

    (in which this Gene is Involved, According to MalaCards, OMIM, UniProtKB, the University of Copenhagen DISEASES database, Novoseek, Genatlas, GeneTests, GAD, HuGE Navigator, and/or TGDB, Sets of similar genes according to GenesLikeMe)
    About This Section

    OMIM gene information: 191170   
    OMIM disorders: 114500  151623  114550  259500  260500  607107  260350  202300  114480  614740  137800  
    UniProtKB/Swiss-Prot: P53_HUMAN, P04637
  • Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently
    mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which
    the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar
    epithelium. The condition develops as a complication in approximately 10% of patients with chronic
    gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma
  • Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are
    esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease
    because it is usually not detected until it has progressed to an advanced incurable stage. Note=The disease is
    caused by mutations affecting the gene represented in this entry
  • Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal dominant familial cancer syndrome that in its classic
    form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative
    affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a
    sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and
    called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of
    malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline
    mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical
    carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15,
    rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric
    cancers. Note=The disease is caused by mutations affecting the gene represented in this entry
  • Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting
    the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.
    Note=The gene represented in this entry is involved in disease pathogenesis
  • Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form
    of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes:
    squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced
    stage and has a poor prognosis. Note=The disease is caused by mutations affecting the gene represented in this
  • Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor of neuroectodermal origin that generally
    occurs in childhood, but has also been reported in adults. Although generally found within the ventricular
    system, choroid plexus papillomas can arise ectopically in the brain parenchyma or disseminate throughout the
    neuraxis. Patients present with signs and symptoms of increased intracranial pressure including headache,
    hydrocephalus, papilledema, nausea, vomiting, cranial nerve deficits, gait impairment, and seizures. Note=The
    disease is caused by mutations affecting the gene represented in this entry
  • Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant neoplasm of the adrenal cortex and a rare
    childhood tumor. It occurs with increased frequency in patients with Beckwith-Wiedemann syndrome and Li-Fraumeni
    syndrome. Note=The disease is caused by mutations affecting the gene represented in this entry
  • Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant skin neoplasm that typically appears on
    hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has
    potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small,
    raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can
    vary from a few millimeters to several centimeters in diameter. Note=Disease susceptibility is associated with
    variations affecting the gene represented in this entry

  • Selected diseases for TP53 (see all 167):    
    About MalaCards
    multifocal osteogenic sarcoma    eyelid neoplasm    basal cell carcinoma 7    ovarian cystic teratoma
    gastrointestinal adenoma    atrophy of prostate    pancreatic serous cystadenoma    hepadnavirus infection
    meningothelial meningioma    breast apocrine carcinoma    glioma susceptibility 1    breast adenoma
    basaloid squamous cell carcinoma    cystic teratoma    li-fraumeni syndrome    adrenocortical carcinoma
    choroid plexus papilloma    nasopharynx carcinoma    intestinal disease    osteosarcoma

    Selected inferred disease relationships from the University of Copenhagen DISEASES database for TP53 (see all 52):
    Carcinoma     Breast cancer     Li-Fraumeni syndrome     Lung cancer
    Retinoblastoma     Colorectal cancer     Malignant glioma     Ovarian cancer
    Urinary bladder cancer     Adenoma     Leukemia     Cervical cancer
    Lymphoma     Hepatocellular carcinoma     Skin cancer     Esophageal cancer
    Endometrial cancer     Melanoma     Pancreatic cancer     Prostate cancer

    Find genes that share disorders with TP53           About GenesLikeMe

    Selected Novoseek inferred disease relationships for TP53 gene (see all 96)    About this table

    Disease   -log (P-Val)   Hits   PubMed IDs for Articles with Shared Sentences (# sentences)
    tumors 93.8 24003 8777377 (10), 7901994 (9), 8007011 (9), 8324748 (8) (see all 99)
    li-fraumeni syndrome 90.7 344 1373881 (5), 17483435 (3), 10980596 (3), 10484981 (3) (see all 99)
    cancer 90.2 7050 17598983 (10), 18223686 (8), 15055300 (7), 12561442 (7) (see all 99)
    carcinoma 87.5 3357 9110348 (10), 8062281 (9), 16033093 (8), 7927312 (8) (see all 99)
    carcinoma squamous cell 86.8 1909 9127380 (8), 8826924 (7), 10445528 (6), 11255264 (6) (see all 99)
    retinoblastoma 85.1 701 10792093 (8), 9337350 (6), 11306502 (5), 8224613 (5) (see all 99)
    microsatellite instability 85 363 9731891 (6), 9716224 (5), 11290569 (5), 12612901 (5) (see all 99)
    allelic loss 83.7 407 16293976 (5), 7909153 (5), 8467510 (4), 11520271 (4) (see all 99)
    adenocarcinoma 82.7 1551 12823203 (7), 17982662 (7), 9379505 (6), 10674608 (6) (see all 99)
    breast cancer 81.9 2818 7917542 (8), 8679460 (8), 12170762 (7), 15566648 (6) (see all 99)

    GeneTests: TP53
    GeneReviews: TP53
    Genetic Association Database (GAD): TP53
    Human Genome Epidemiology (HuGE) Navigator: TP53 (1074 documents)
    Tumor Gene Database (TGDB): TP53

    Export disorders for TP53 gene to outside databases

    (in PubMed. Associations of this gene to articles via 1Entrez Gene, 2UniProtKB/Swiss-Prot, 3HGNC, 4GAD, 5PharmGKB, 6HMDB, 7DrugBank, 8UniProtKB/TrEMBL, 9 Novoseek, and/or 10fRNAdb)
    About This Section

    PubMed articles for TP53 gene, integrated from 10 sources (see all 15580) (see top 10):
    (articles sorted by number of sources associating them with TP53)

    1. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. (PubMed id 6396087)1, 2, 3 Matlashewski G....Benchimol S. (EMBO J. 1984)
    2. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer. (PubMed id 19434453)1, 4, 9 Chien W.P....Lee H. (Ann. Surg. Oncol. 2009)
    3. Mutations in p53, p53 protein overexpression and breast cancer survival. (PubMed id 19602056)1, 4, 9 Rossner P....Santella R.M. (J. Cell. Mol. Med. 2009)
    4. TP53 mutations in endometrial cancers: relation to PTEN gene defects. (PubMed id 20169661)1, 4, 9 Janiec-Jankowska A....NajmoA8a U. (Int. J. Gynecol. Cancer 2010)
    5. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). (PubMed id 19096301)1, 4, 9 Lim E.H....Tan P. (J Thorac Oncol 2009)
    6. FAK overexpression and p53 mutations are highly correlated in human breast cancer. (PubMed id 19521985)1, 4, 9 Golubovskaya V.M....Cance W.G. (Int. J. Cancer 2009)
    7. [Mutations of p53 gene in 41 cases of human brain gliomas]. (PubMed id 18184456)1, 4, 9 Cui W....Wang X.C. (Ai Zheng 2008)
    8. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. (PubMed id 17595776)1, 4, 9 Bau D.T....Tsai F.J. (Anticancer Res. 2007)
    9. TP53 mutations in breast cancer tumors of patients from Rio de Janeiro, Brazil: association with risk factors and tumor characteristics. (PubMed id 12209590)1, 4, 9 SimALo Moura-Gallo C.V. (Int. J. Cancer 2002)
    10. Mutations in the p53 tumor suppressor gene and early onset breast cancer. (PubMed id 12170762)1, 4, 9 Lai H....Meng L. (amp 2002)
    11. Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family. (PubMed id 10484981)1, 2, 9 Gueran S.... Imirzalioglu N. (Cancer Genet. Cytogenet. 1999)
    12. Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. (PubMed id 19048399)1, 4, 9 Akkiprik M....Ozer A. (Pathol. Oncol. Res. 2009)
    13. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. (PubMed id 18462472)1, 4, 9 Zawlik I....Ohgaki H. (Brain Pathol. 2009)
    14. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. (PubMed id 19536131)1, 2, 9 Lee E.-W.... Song J. (EMBO J. 2009)
    15. Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients. (PubMed id 19578553)1, 4, 9 Saglar E....Ogus A. (Mol. Vis. 2009)
    16. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. (PubMed id 19193430)1, 4, 9 Ashton K.A....Scott R.J. (Gynecol. Oncol. 2009)
    17. Association study of TP53 polymorphisms with lung cancer in a Korean population. (PubMed id 18363031)1, 4, 9 Jung H.Y....Kim Y.H. (J. Hum. Genet. 2008)
    18. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. (PubMed id 17259658)1, 4, 9 MollevA- D.G....Villanueva A. (Carcinogenesis 2007)
    19. Breast-cancer stromal cells with TP53 mutations and nodal metastases. (PubMed id 18094375)1, 4, 9 Patocs A....Eng C. (N. Engl. J. Med. 2007)
    20. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. (PubMed id 16697770)1, 4, 9 Lee Y.L....Wang Y.C. (J. Lab. Clin. Med. 2006)
    21. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? (PubMed id 11255264)1, 4, 9 Bastiaens M.T....ter Schegget J. (Mol. Carcinog. 2001)
    22. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. (PubMed id 8875929)1, 2, 9 Kussie P.H.... Pavletich N.P. (Science 1996)
    23. Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. (PubMed id 20110284)1, 4, 9 Naccarati A....Vodicka P. (Carcinogenesis 2010)
    24. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. (PubMed id 20520810)1, 4, 9 Fang S....Amos C.I. (PLoS ONE 2010)
    25. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. (PubMed id 20363586)1, 4, 9 Tang N.P....Ma J. (Eur J Surg Oncol 2010)
    26. The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. (PubMed id 19153488)1, 4, 9 Oki E....Maehara Y. (Digestion 2009)
    27. Genetic polymorphisms, messenger RNA expression of p53, p21, and CCND1, and possible links with chromosomal aberrations in Chinese vinyl chloride-exposed workers. (PubMed id 18842998)1, 4, 9 Qiu Y.L....Xia Z.L. (amp 2008)
    28. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. (PubMed id 17151932)1, 4, 9 Malmer B.S....Henriksson R. (J. Neurooncol. 2007)
    29. [p53 Codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans]. (PubMed id 18159160)1, 4, 9 Kim J.M....Lee D.H. (Korean J Gastroenterol 2007)
    30. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? (PubMed id 17622940)1, 4, 9 Tan X.L....Chang-Claude J. (Pharmacogenet. Genomics 2007)
    31. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. (PubMed id 16314399)1, 4, 9 Ma H....Shen H. (Carcinogenesis 2006)
    32. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]. (PubMed id 16750013)1, 4, 9 Yuan P....Lin D.X. (Zhonghua Zhong Liu Za Zhi 2006)
    33. Association of breast cancer outcome with status of p53 and MDM2 SNP309. (PubMed id 16818855)1, 4, 9 Boersma B.J....Ambs S. (J. Natl. Cancer Inst. 2006)
    34. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. (PubMed id 16835330)1, 4, 9 Rohan T.E....Kandel R.A. (amp 2006)
    35. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. (PubMed id 16644204)1, 4, 9 Lalloo F....Evans D.G. (Eur. J. Cancer 2006)
    36. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. (PubMed id 16434604)1, 4, 9 Schabath M.B....Spitz M.R. (amp 2006)
    37. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. (PubMed id 15906354)1, 4, 9 Kelsey K.T....Karagas M. (Int. J. Cancer 2005)
    38. [Association of the p53 codon 72 polymorphism to gastric cancer risk in a hight risk population of Costa Rica]. (PubMed id 17354442)1, 4, 9 AlpA-zar-AlpA-zar W....PAcrez-PAcrez G.I. (Rev. Biol. Trop. 2005)
    39. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. (PubMed id 16203772)1, 4, 9 Sotamaa la Chapelle A. (Clin. Cancer Res. 2005)
    40. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. (PubMed id 15564800)1, 4, 9 Hedau S....Das B.C. (Breast Cancer Res. Treat. 2004)
    41. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. (PubMed id 14741326)1, 4, 9 Park J.K....Chung J.H. (Schizophr. Res. 2004)
    42. TP53 codon 72 polymorphism does not affect risk of cervical cancer in patients from The Gambia. (PubMed id 14756543)1, 4, 9 Tanara G....Cosimi A. (Int. J. Biol. Markers 2003)
    43. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. (PubMed id 12820330)1, 4, 9 Ecke T.H....Loening S.A. (Anticancer Res. 2003)
    44. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. (PubMed id 12802680)1, 4, 9 Hwang S.J....Strong L.C. (Hum. Genet. 2003)
    45. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. (PubMed id 12684392)1, 4, 9 Berns E.M....Foekens J.A. (Clin. Cancer Res. 2003)
    46. [p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population]. (PubMed id 12921568)1, 4, 9 Zhang J.H....He M. (Zhonghua Zhong Liu Za Zhi 2003)
    47. p53 Codon 72 polymorphism and urothelial cancer risk. (PubMed id 12445680)1, 4, 9 Kuroda Y....Katoh T. (Cancer Lett. 2003)
    48. p53 codon 72 polymorphism and its association with bladder cancer. (PubMed id 11888672)1, 4, 9 Soulitzis N....Spandidos D.A. (Cancer Lett. 2002)
    49. Mutations in TP53 tumor suppressor gene in wood dust-related sinonasal cancer. (PubMed id 19950227)1, 4, 9 Holmila R....Husgafvel-Pursiainen K. (Int. J. Cancer 2010)
    50. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. (PubMed id 19629678)1, 4, 9 Zhang Z....Zhang Z. (Breast Cancer Res. Treat. 2010)
    51. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. (PubMed id 19682377)1, 4, 9 Zhuo W....Chen Z. (amp 2009)
    52. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. (PubMed id 19426493)1, 4, 9 GallA- P....Boccia S. (BMC Cancer 2009)
    53. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. (PubMed id 19367287)1, 4, 9 Oden-Gangloff A....Frebourg T. (Br. J. Cancer 2009)
    54. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. (PubMed id 19141386)1, 4, 9 Ruano Y....MelAcndez B. (Am. J. Clin. Pathol. 2009)
    55. Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. (PubMed id 19198855)1, 4, 9 Chang S.C....Lin J.K. (Int J Colorectal Dis 2009)
    56. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. (PubMed id 19096302)1, 4, 9 Kosaka T....Mitsudomi T. (J Thorac Oncol 2009)
    57. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. (PubMed id 19339276)1, 4, 9 Katkoori V.R....Manne U. (Clin. Cancer Res. 2009)
    58. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. (PubMed id 18348141)1, 4, 9 Xu Y....Xie Y. (Int. J. Cancer 2008)
    59. p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia. (PubMed id 19145674)1, 4, 9 Malisic E....Radulovic S. (J BUON 2008)
    60. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. (PubMed id 18367114)1, 4, 9 Ecke T.H....Loening S.A. (Urol. Oncol. 2008)
    61. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. (PubMed id 18656689)1, 4, 9 Bumroongkit K....Kangwanpong D. (Cancer Genet. Cytogenet. 2008)
    62. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. (PubMed id 17693666)1, 4, 9 Chen K....Wei Q. (Carcinogenesis 2007)
    63. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. (PubMed id 16287156)1, 4, 9 Zhang X....Lin D. (Hum. Mutat. 2006)
    64. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. (PubMed id 16818665)1, 4, 9 Gormally E....Hainaut P. (Cancer Res. 2006)
    65. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. (PubMed id 16499995)1, 4, 9 Szymanowska A....Jassem J. (Lung Cancer 2006)
    66. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. (PubMed id 16289646)1, 4, 9 Lai K.C....Tsai F.J. (Eur J Surg Oncol 2005)
    67. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. (PubMed id 16054204)1, 4, 9 Bhattacharya P. and Sengupta S. (Gynecol. Oncol. 2005)
    68. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. (PubMed id 16110022)1, 4, 9 Westra J.L....Plukker J.T. (J. Clin. Oncol. 2005)
    69. [Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer]. (PubMed id 16161633)1, 4, 9 Tarasov V.A....Mel'nik V.A. (Genetika 2005)
    70. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. (PubMed id 16354872)1, 4, 9 Jain N....Das B.C. (Chest 2005)
    71. Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer. (PubMed id 14764039)1, 4, 9 Lee J.E....Park J.S. (Int. J. Gynecol. Cancer 2004)
    72. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. (PubMed id 15069555)1, 4, 9 Shen H....Wei Q. (Oncol. Rep. 2004)
    73. Association of p53 arginine polymorphism with skin cancer. (PubMed id 15230885)1, 4, 9 de Oliveira W.R....Tyring S.K. (Int. J. Dermatol. 2004)
    74. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. (PubMed id 15355915)1, 4, 9 Jones J.S....Frazier M.L. (Clin. Cancer Res. 2004)
    75. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. (PubMed id 12824702)1, 4, 9 Suzuki K....Yamanaka H. (J. Biomed. Sci. 2003)
    76. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. (PubMed id 12635827)1, 4, 9 Chen Y.C....Christiani D.C. (amp 2003)
    77. Mutation of the p53 gene predicts lymph node metastases in Japanese patients with esophageal carcinoma: DNA and immunohistochemical analyses. (PubMed id 14641293)1, 4, 9 Hattori K....Tsurumaru M. (Dis. Esophagus 2003)
    78. The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. (PubMed id 14507241)1, 4, 9 Kietthubthew S....Ishida T. (Asian Pac. J. Cancer Prev. 2003)
    79. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. (PubMed id 14581358)1, 4, 9 BonafAc M....Franceschi C. (Clin. Cancer Res. 2003)
    80. Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis. (PubMed id 12161031)1, 4, 9 Kuhlmann T....BrA1ck W. (J. Neuroimmunol. 2002)
    81. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. (PubMed id 12144822)1, 4, 9 Saranath D....Dinshaw K. (Gynecol. Oncol. 2002)
    82. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. (PubMed id 11146230)1, 4, 9 Peixoto Guimaraes D....Hainaut P. (Cancer Lett. 2001)
    83. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia. (PubMed id 20414935)1, 4, 9 Malisic E....Radulovic S. (J BUON 2010)
    84. Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. (PubMed id 20082853)1, 4, 9 Ghasemi N....Atash-Afza A. (Cancer Genet. Cytogenet. 2010)
    85. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. (PubMed id 20137853)1, 4, 9 SzymaA8ska K....Brennan P. (Cancer Lett. 2010)
    86. Decreased PM10 exposure attenuates age-related lung function decline: genetic variants in p53, p21, and CCND1 modify this effect. (PubMed id 19750108)1, 4, 9 Imboden M....Probst-Hensch N.M. (Environ. Health Perspect. 2009)
    87. Mutational spectrum of conserved regions of TP53 and PTEN genes in Kangri cancer (of the skin) in the Kashmiri population. (PubMed id 19486858)1, 4, 9 Hussain I....Siddiqi M.A. (Mutat. Res. 2009)
    88. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. (PubMed id 19764997)1, 4, 9 Shinohara A....Matsuyama H. (Cancer Sci. 2009)
    89. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. (PubMed id 19357867)1, 4, 9 Dai S....Cheng H. (Hum. Genet. 2009)
    90. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. (PubMed id 19171829)1, 4, 9 El Hallani S....Sanson M. (Neurology 2009)
    91. Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients. (PubMed id 19072763)1, 4, 9 Gao W....Keohavong P. (Mol. Carcinog. 2009)
    92. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. (PubMed id 19247656)1, 4, 9 Huang Z.H....Du X. (Cancer Chemother. Pharmacol. 2009)
    93. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. (PubMed id 19386249)1, 4, 9 De Feo E....Boccia S. (Mutat. Res. 2009)
    94. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (PubMed id 19234440)1, 4, 9 Inamura K....Ishikawa Y. (Mod. Pathol. 2009)
    95. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. (PubMed id 19178978)1, 4, 9 Li Y....Song Y. (Lung Cancer 2009)
    96. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. (PubMed id 19239324)1, 4, 9 Cao Z....Park W.S. (Neoplasma 2009)
    97. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. (PubMed id 19234438)1, 4, 9 Catasus L....Prat J. (Mod. Pathol. 2009)
    98. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. (PubMed id 18379354)1, 4, 9 Ludovini V....Tonato M. (J Thorac Oncol 2008)
    99. Polymorphism of XRCC1 and the frequency of mutation in codon 249 of the p53 gene in hepatocellular carcinoma among Guangxi population, China. (PubMed id 17849423)1, 4, 9 Long X.D....Lu Y.L. (Mol. Carcinog. 2008)
    100. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. (PubMed id 18402691)1, 4, 9 Cavallone L....Tonin P.N. (BMC Cancer 2008)
    101. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. (PubMed id 19020536)1, 4, 9 Agell L....Lloreta J. (Mod. Pathol. 2008)
    102. TP53 gene mutations as an independent marker for urinary bladder cancer progression. (PubMed id 18425359)1, 4, 9 Ecke T.H....Schlechte H.H. (Int. J. Mol. Med. 2008)
    103. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. (PubMed id 17541742)1, 4, 9 Arcand S.L....Tonin P.N. (Breast Cancer Res. Treat. 2008)
    104. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. (PubMed id 18988302)1, 4, 9 Zhu Z.Z....Zhu G.S. (J Zhejiang Univ Sci B 2008)
    105. p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases. (PubMed id 18803266)1, 4, 9 Chen R.H....Tsai F.J. (J. Clin. Lab. Anal. 2008)
    106. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer]. (PubMed id 18393238)1, 4, 9 Wang A.Z....Cong W.M. (Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008)
    107. Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. (PubMed id 18593981)1, 4, 9 Huang J....Ohgaki H. (Clin. Cancer Res. 2008)
    108. An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. (PubMed id 17208332)1, 4, 9 Nadji S.A....Mokhtari-Azad T. (Lung Cancer 2007)
    109. Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma. (PubMed id 17587242)1, 4, 9 Mitani S....Mori S. (Pathol. Int. 2007)
    110. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. (PubMed id 17428325)1, 4, 9 Baynes C....Dunning A.M. (Breast Cancer Res. 2007)
    111. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. (PubMed id 16996204)1, 4, 9 Eachkoti R....Siddiqi M.A. (Cancer Lett. 2007)
    112. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. (PubMed id 17546594)1, 4, 9 Zhou Y....Wu X.T. (Int. J. Cancer 2007)
    113. [Study on the relationship between the polymorphism of p53 gene intron 7 and non-small cell lung cancer (NSCLC) and p53 mutation in NSCLC tissues]. (PubMed id 17557246)1, 4, 9 Gu Q.H....Yang H.Z. (Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007)
    114. P53 mutations in urinary bladder cancer patients from Central Poland. (PubMed id 17495352)1, 4, 9 Borkowska E....KaA8uzewski B. (J. Appl. Genet. 2007)
    115. P53 gene mutations in surgical margins and primary tumor tissues of patients with squamous cell carcinoma of the head and neck. (PubMed id 17557566)1, 4, 9 Tunca B....Egeli U. (Tumori 2007)
    116. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. (PubMed id 18006764)1, 4, 9 Huang S.P....Wu M.T. (Clin. Cancer Res. 2007)
    117. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. (PubMed id 17341484)1, 4, 9 Johnson N....Peto J. (Hum. Mol. Genet. 2007)
    118. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. (PubMed id 17912468)1, 4, 9 Sousa H....Medeiros R. (Int. J. Mol. Med. 2007)
    119. Genetic status of p53 in stomach cancer: somatic mutations and polymorphism of codon 72. (PubMed id 16984108)1, 4, 9 Belyavskaya V.A....Voevoda M.I. (Bull. Exp. Biol. Med. 2006)
    120. Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. (PubMed id 16488468)1, 4, 9 Gudleviciene Z....Valuckas K.P. (Gynecol. Oncol. 2006)
    121. A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. (PubMed id 17072987)1, 4, 9 Yi S.Y. and Lee W.J. (World J. Gastroenterol. 2006)
    122. [P53 codon 72 polymorphism in cervical cancers and its correlation with HPV16,18E6]. (PubMed id 16761419)1, 4, 9 Hou M.M....Sun Z.L. (Sichuan Da Xue Xue Bao Yi Xue Ban 2006)
    123. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. (PubMed id 16552814)1, 4, 9 PAcrez L.O....Golijow C.D. (World J. Gastroenterol. 2006)
    124. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers. (PubMed id 16721749)1, 4, 9 Huang C.C....Lee H. (Environ. Mol. Mutagen. 2006)
    125. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. (PubMed id 16808798)1, 4, 9 Wu X....Jiang W.J. (Chin J Dig Dis 2006)
    126. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. (PubMed id 16144912)1, 4, 9 Feng Y.Z....Konishi I. (Clin. Cancer Res. 2005)
    127. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. (PubMed id 16024113)1, 4, 9 Eriksen J.G....Overgaard J. (Radiother Oncol 2005)
    128. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. (PubMed id 15814626)1, 4, 9 Hu Y....Ahrendt S.A. (Clin. Cancer Res. 2005)
    129. Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. (PubMed id 15023836)1, 4, 9 Ronchetti D....Pignataro L. (amp 2004)
    130. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. (PubMed id 15764300)1, 4, 9 Chen Y.C....Christiani D.C. (Biomarkers 2004)
    131. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. (PubMed id 15598783)1, 4, 9 Huang S.P....Huang C.H. (amp 2004)
    132. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. (PubMed id 15263792)1, 4, 9 Wu H.C....Chen W.C. (Urol. Int. 2004)
    133. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. (PubMed id 14673037)1, 4, 9 Nichols K.E....Diller L. (J. Clin. Oncol. 2003)
    134. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. (PubMed id 11983757)1, 4, 9 Wu X....Spitz M.R. (J. Natl. Cancer Inst. 2002)
    135. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. (PubMed id 12445252)1, 4, 9 Arbel-Alon S....Friedman E. (Int. J. Gynecol. Cancer 2002)
    136. [p53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population]. (PubMed id 11836677)1, 4, 9 Zhang L....Lin D. (Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002)
    137. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. (PubMed id 11504770)1, 4, 9 Smith J.S....Jenkins R.B. (J. Natl. Cancer Inst. 2001)
    138. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. (PubMed id 11447225)1, 2, 9 Xie S.... Dai W. (J. Biol. Chem. 2001)
    139. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. (PubMed id 10884347)1, 2, 9 Luciani M.G.... Hupp T.R. (J. Mol. Biol. 2000)
    140. The p53 codon 72 polymorphism and lung cancer risk. (PubMed id 11045785)1, 4, 9 Fan R....Christiani D.C. (amp 2000)
    141. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. (PubMed id 8829627)1, 2, 9 Audrezet M.-P.... Ferec C. (Hum. Mutat. 1996)
    142. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. (PubMed id 1349102)1, 4, 9 Crook T....Vousden K.H. (Lancet 1992)
    143. p53 mutations in colorectal cancer. (PubMed id 1699228)1, 2, 9 Rodrigues N.R.... Lane D.P. (Proc. Natl. Acad. Sci. U.S.A. 1990)
    144. TP53, MDM2, NQO1, and susceptibility to cervical cancer. (PubMed id 20200430)1, 4, 9 Hu X....Rader J.S. (amp 2010)
    145. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma. (PubMed id 19954744)1, 4, 9 Acun T....Yakicier M.C. (Mutat. Res. 2010)
    146. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. (PubMed id 19941079)1, 4, 9 Chien W.P....Lee H. (Ann. Surg. Oncol. 2010)
    147. Association between TP53 gene ARG72PRO polymorphism and chromosome aberrations in human cancers. (PubMed id 20512840)1, 4, 9 Litviakov N.V....Koshel A.P. (Mol. Carcinog. 2010)
    148. High frequency of de novo mutations in Li-Fraumeni syndrome. (PubMed id 19556618)1, 4, 9 Gonzalez K.D....Sommer S.S. (J. Med. Genet. 2009)
    149. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. (PubMed id 19672255)1, 4, 9 Chua W....Iacopetta B. (Br. J. Cancer 2009)
    150. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. (PubMed id 19954513)1, 4, 9 Godai T.I....Miyagi Y. (BMC Cancer 2009)
    151. Ethnic differences and functional analysis of MET mutations in lung cancer. (PubMed id 19723643)1, 4, 9 Krishnaswamy S....Salgia R. (Clin. Cancer Res. 2009)
    152. Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. (PubMed id 19760750)1, 4, 9 Li J....Makrigiorgos G.M. (Hum. Mutat. 2009)
    153. Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. (PubMed id 19224462)1, 4, 9 Almeida L.O....Casartelli C. (Genet. Mol. Res. 2009)
    154. Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease. (PubMed id 19543899)1, 4, 9 Rapozo D.C....Pinto L.F. (Int J Colorectal Dis 2009)
    155. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. (PubMed id 19052714)1, 4, 9 Kim J.G....Yu W. (Cancer Chemother. Pharmacol. 2009)
    156. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. (PubMed id 18706692)1, 4, 9 Zainuddin N....Enblad G. (Leuk. Res. 2009)
    157. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. (PubMed id 19625214)1, 4, 9 Klug S.J....Blettner M. (Lancet Oncol. 2009)
    158. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. (PubMed id 19594747)1, 4, 9 Jardin F....Tilly H. (Br. J. Haematol. 2009)
    159. Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women. (PubMed id 19430562)1, 4, 9 Cho Y.H....Kim Y.T. (Yonsei Med. J. 2009)
    160. Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis. (PubMed id 19482343)1, 4, 9 Zhou X....Shen H. (Gynecol. Oncol. 2009)
    161. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. (PubMed id 19423162)1, 4, 9 Xiong X....Wang J. (Leuk. Res. 2009)
    162. Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. (PubMed id 19423538)1, 4, 9 Koshiol J....Wang S.S. (amp 2009)
    163. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. (PubMed id 19643983)1, 4, 9 Zenz T....Stilgenbauer S. (Blood 2009)
    164. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. (PubMed id 18559976)1, 4, 9 Young K.H....Greiner T.C. (Blood 2008)
    165. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. (PubMed id 18322661)1, 4, 9 Vidaurreta M....Torres A. (Int J Colorectal Dis 2008)
    166. Concomitant presence of mutations in mitochondrial genome and p53 in cancer development - a study in north Indian sporadic breast and esophageal cancer patients. (PubMed id 18792899)1, 4, 9 Gochhait S....Bamezai R.N. (Int. J. Cancer 2008)
    167. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. (PubMed id 18357466)1, 4, 9 Huang Z.H....Zhu J.D. (J. Cancer Res. Clin. Oncol. 2008)
    168. Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers. (PubMed id 18820009)1, 4, 9 Hamaguchi M....Yamashita H. (Jpn. J. Clin. Oncol. 2008)
    169. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. (PubMed id 18612219)1, 4, 9 Vannini I....Bonafe M. (Tumour Biol. 2008)
    170. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. (PubMed id 18172257)1, 4, 9 Bartel F....Hauptmann S. (Clin. Cancer Res. 2008)
    171. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. (PubMed id 18555592)1, 4, 9 Hassan N.M....Moriuchi T. (Cancer Lett. 2008)
    172. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. (PubMed id 17949449)1, 4, 9 Ahmed I.A....Lunec J. (Colorectal Dis 2008)
    173. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. (PubMed id 18510673)1, 4, 9 Nan H....Han J. (Br. J. Dermatol. 2008)
    174. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. (PubMed id 17954263)1, 4, 9 Hadhri-Guiga B....Mokdad-Gargouri R. (Cancer Genet. Cytogenet. 2007)
    175. Germ-line genetic variation of TP53 in osteosarcoma. (PubMed id 17096406)1, 4, 9 Savage S.A....Chanock S.J. (amp 2007)
    176. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. (PubMed id 17369602)1, 4, 9 Di Leo A....Isola J. (Ann. Oncol. 2007)
    177. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. (PubMed id 17881637)1, 4, 9 Young K.H....Greiner T.C. (Blood 2007)
    178. [Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival]. (PubMed id 18314620)1, 4, 9 BAPhnke A....Bartel F. (Verh Dtsch Ges Pathol 2007)
    179. p53 Gene mutations in sporadic colorectal carcinoma in Guangxi region. (PubMed id 17118779)1, 4, 9 Gao F....Tang W. (Cancer Invest. 2006)
    180. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. (PubMed id 16459017)1, 4, 9 Ueno Y....Murata Y. (Cancer Lett. 2006)
    181. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. (PubMed id 16912210)1, 4, 9 Wu C.C....Strong L.C. (Cancer Res. 2006)
    182. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers. (PubMed id 16865671)1, 4, 9 Gao W.M....Keohavong P. (Mol. Carcinog. 2006)
    183. p53 codon 72 polymorphism in basal cell carcinoma of the skin. (PubMed id 16554913)1, 4, 9 Pezeshki A....Doroudchi M. (Pathol. Oncol. Res. 2006)
    184. Germline polymorphism of p53 codon 72 in gynecological cancer. (PubMed id 16168468)1, 4, 9 Ueda M....Ueki M. (Gynecol. Oncol. 2006)
    185. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. (PubMed id 17177838)1, 4, 9 Min-min H....Zhi-lin S. (Int. J. Gynecol. Cancer 2006)
    186. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. (PubMed id 16364249)1, 4, 9 Santos A.M....Medeiros R. (Biochem. Biophys. Res. Commun. 2006)
    187. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. (PubMed id 17374954)1, 4, 9 Perfumo C....Varesco L. (Digestion 2006)
    188. p53 intronic G13964C variant in colon cancer and its association with HPV. (PubMed id 16080524)1, 4, 9 Buyru N....Dalay N. (Anticancer Res. 2005)
    189. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. (PubMed id 15950766)1, 4, 9 Parhar P....Newcomb E.W. (Brain Res. Mol. Brain Res. 2005)
    190. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. (PubMed id 16229746)1, 4, 9 Kringen P....Dorum A. (BMC Cancer 2005)
    191. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. (PubMed id 15966238)1, 4, 9 Lai K.C....Jeng L.B. (Hepatogastroenterology 2005)
    192. Human papillomavirus genotypes and the p53 codon 72 polymorphism in cervical cancer of Northeastern Thailand. (PubMed id 15905603)1, 4, 9 Settheetham-Ishida W....Ishida T. (Microbiol. Immunol. 2005)
    193. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. (PubMed id 16211227)1, 4, 9 Arcand S.L....Tonin P.N. (Int. J. Oncol. 2005)
    194. Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. (PubMed id 16362795)1, 4, 9 Khayat A.S....Burbano R.R. (Clin. Exp. Med. 2005)
    195. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. (PubMed id 15841715)1, 4, 9 PAcrez-PAcrez G.I....Garza-GonzA!lez E. (Scand. J. Gastroenterol. 2005)
    196. The role of p53 codon 72 and human papilloma virus status of cutaneous squamous cell carcinoma in the Swedish population. (PubMed id 15844633)1, 4, 9 Gustafsson A.C....Lundeberg J. (Acta Derm. Venereol. 2004)
    197. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. (PubMed id 15240512)1, 4, 9 Xi Y.G....Ke Y. (Carcinogenesis 2004)
    198. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. (PubMed id 15183530)1, 4, 9 Granja F....Ward L.S. (Cancer Lett. 2004)
    199. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. (PubMed id 15041222)1, 4, 9 Cortezzi S.S....Rahal P. (Cancer Genet. Cytogenet. 2004)
    200. [Correlation between P53 codon 72 polymorphism and tumorigenesis of cervical cancer]. (PubMed id 15566643)1, 4, 9 Li C.Y....Huang B.J. (Ai Zheng 2004)
    201. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. (PubMed id 15105048)1, 4, 9 Leveri M....Silini E.M. (Cancer Lett. 2004)
    202. Analysis of the codon 72 polymorphism of the TP53 gene in patients with endometriosis. (PubMed id 15273281)1, 4, 9 Lattuada D....Di Blasio A.M. (Mol. Hum. Reprod. 2004)
    203. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. (PubMed id 15554555)1, 4, 9 Agorastos T....Bontis I. (Eur. J. Cancer Prev. 2004)
    204. A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. (PubMed id 15104366)1, 4, 9 Zhang Z.W....Holly J. (Dig. Dis. Sci. 2004)
    205. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish &quot;Malova&quot; Ovarian Cancer Study. (PubMed id 12926080)1, 4, 9 HA...Hogdall C.K. (Anticancer Res. 2003)
    206. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. (PubMed id 14678586)1, 4, 9 Inserra P....Giuliano A.R. (amp 2003)
    207. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. (PubMed id 14660794)1, 2, 9 Kanashiro C.A....Varga J.L. (Proc. Natl. Acad. Sci. U.S.A. 2003)
    208. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. (PubMed id 12907646)1, 4, 9 Leslie A....Steele R.J. (Cancer Res. 2003)
    209. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. (PubMed id 14577584)1, 4, 9 Katiyar S....Das B.C. (Mol. Cell. Biochem. 2003)
    210. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. (PubMed id 12810724)1, 2, 9 Louria-Hayon I....Haupt Y. (J. Biol. Chem. 2003)
    211. The proline form of p53 codon 72 polymorphism is associated with endometriosis. (PubMed id 11779589)1, 4, 9 Chang C.C....Lin C.C. (Fertil. Steril. 2002)
    212. [Study on the relationship between cervical cancer and p53 codon 72 polymorphism]. (PubMed id 12575207)1, 4, 9 Qie M....Wu J. (Hua Xi Yi Ke Da Xue Xue Bao 2002)
    213. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. (PubMed id 12496062)1, 4, 9 LangerA...rresen-Dale A.L. (amp 2002)
    214. Distribution of p53 codon 72 polymorphism in Indian primary open angle glaucoma patients. (PubMed id 12368717)1, 4, 9 Acharya M....Ray K. (Mol. Vis. 2002)
    215. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. (PubMed id 11807792)1, 4, 9 Nagpal J.K....Das B.R. (Int. J. Cancer 2002)
    216. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. (PubMed id 12144687)1, 4, 9 Pegoraro R.J....Moodley J. (Int. J. Gynecol. Cancer 2002)
    217. P53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women. (PubMed id 12534455)1, 4, 9 Nagpal J.K....Das B.R. (Eur. J. Clin. Invest. 2002)
    218. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. (PubMed id 12467072)1, 4, 9 Li T....Ke Y. (Cancer 2002)
    219. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. (PubMed id 11458982)1, 4, 9 Sayhan N....Dalay N. (Res. Commun. Mol. Pathol. Pharmacol. 2001)
    220. P53 codon 72 polymorphism in bladder cancer--no evidence of association with increased risk or invasiveness. (PubMed id 11828992)1, 4, 9 TAPrA1ner G.A....OzAselik T. (Urol. Res. 2001)
    221. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. (PubMed id 11429426)1, 4, 9 O'Connor D.P....Mabruk M.J. (J. Clin. Pathol. 2001)
    222. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. (PubMed id 11746272)1, 4, 9 Henner W.D....Beer T.M. (Prostate 2001)
    223. p53 codon 72 polymorphism in cervical cancer patients and healthy women from Poland. (PubMed id 11996107)1, 4, 9 Dybikowska A....Podhajska A. (Acta Biochim. Pol. 2000)
    224. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. (PubMed id 8118819)1, 2, 9 Birch J.M.... Santibanez-Koref M.F. (Cancer Res. 1994)
    225. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. (PubMed id 7682763)1, 2, 9 Caamano J.... Klein-Szanto A.J.P. (Am. J. Pathol. 1993)
    226. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. (PubMed id 1933902)1, 2, 9 Law J.C.... Ferrell R.E. (Cancer Res. 1991)
    227. Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors. (PubMed id 1647768)1, 2, 9 Ishioka C.... Yamazaki T. (Biochem. Biophys. Res. Commun. 1991)
    228. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. (PubMed id 19810096)1, 4, 9 Tominaga T....Yamaue H. (Int. J. Cancer 2010)
    229. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. (PubMed id 20006376)1, 4, 9 Lee E.J....Kim B.G. (Gynecol. Oncol. 2010)
    230. Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors. (PubMed id 20432164)1, 4, 9 Slattery M.L....Samowitz W. (Nutr Cancer 2010)
    231. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women. (PubMed id 20193851)1, 4, 9 Jiang P....Tang J. (Cancer Genet. Cytogenet. 2010)
    232. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. (PubMed id 20514470)1, 4, 9 Gao W....Keohavong P. (Oncol. Rep. 2010)
    233. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. (PubMed id 19941080)1, 4, 9 Yamasaki M....Doki Y. (Ann. Surg. Oncol. 2010)
    234. BRD7 is a candidate tumour suppressor gene required for p53 function. (PubMed id 20228809)1, 2, 9 Drost J.... Del Sal G. (Nat. Cell Biol. 2010)
    235. Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study. (PubMed id 19626602)1, 4, 9 Zheng Y.L....Harris C.C. (Int. J. Cancer 2010)
    236. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. (PubMed id 19837266)1, 4, 9 Do T.N....Dorak M.T. (Cancer Genet. Cytogenet. 2009)
    237. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. (PubMed id 19470478)1, 4, 9 Kang H.J....Hu W. (Proc. Natl. Acad. Sci. U.S.A. 2009)
    238. TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. (PubMed id 19468865)1, 4, 9 Pinto C....Teixeira M.R. (Fam. Cancer 2009)
    239. Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms. (PubMed id 19521721)1, 4, 9 Hancox R.J....Braithwaite A.W. (Hum. Genet. 2009)
    240. Human papillomavirus and p53 polymorphism in codon 72 in head and neck squamous cell carcinoma. (PubMed id 19212643)1, 4, 9 Hoffmann M....Gottschlich S. (Oncol. Rep. 2009)
    241. Germline TP53 mutations and single nucleotide polymorphisms in children. (PubMed id 19414295)1, 4, 9 Valva P....Preciado M.V. (Medicina (B Aires) 2009)
    242. The RR genotype of codon 72 of p53 gene reduces the development of intestinal metaplasia. (PubMed id 18567547)1, 4, 9 Szoke D....Tulassay Z. (Dig Liver Dis 2009)
    243. Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors. (PubMed id 19909015)1, 4, 9 Ouerhani S....Benammar Elgaaied A. (Cancer Invest. 2009)
    244. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. (PubMed id 19026650)1, 4, 9 Zou H....Ahlquist D.A. (Gastroenterology 2009)
    245. Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. (PubMed id 19151620)1, 4, 9 Watanabe T....Ohgaki H. (J. Neuropathol. Exp. Neurol. 2009)
    246. TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. (PubMed id 19940524)1, 4, 9 Tornesello M.L....Buonaguro F.M. (Oncology 2009)
    247. Microsatellite instability and survival in rectal cancer. (PubMed id 19669908)1, 4, 9 Samowitz W.S....Slattery M.L. (amp 2009)
    248. The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. (PubMed id 19209008)1, 4, 9 Zubor P....Danko J. (Oncology 2009)
    249. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. (PubMed id 19151774)1, 4, 9 Seifert H....Schaich M. (Leukemia 2009)
    250. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. (PubMed id 19246647)1, 4, 9 Watanabe T....Ohgaki H. (Am. J. Pathol. 2009)
    251. Integrative approach for prioritizing cancer genes in sporadic colon cancer. (PubMed id 19672874)1, 4, 9 Reid J.F....Pierotti M.A. (amp 2009)
    252. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. (PubMed id 19204927)1, 4, 9 Misra C....Roychoudhury S. (Mol. Carcinog. 2009)
    253. Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. (PubMed id 20082880)1, 4, 9 Zhuo X.L....Zhang X.Y. (Arch. Med. Res. 2009)
    254. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. (PubMed id 19204208)1, 4, 9 Gonzalez K.D....Weitzel J.N. (J. Clin. Oncol. 2009)
    255. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. (PubMed id 19383811)1, 4, 9 Cescon D.W....Liu G. (Clin. Cancer Res. 2009)
    256. [Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma]. (PubMed id 19650989)1, 4, 9 Feng L.J....Dai M. (Zhongguo Dang Dai Er Ke Za Zhi 2009)
    257. p53 codon 72 polymorphism and HPV status in lung cancer. (PubMed id 18758421)1, 4, 9 Buyru N....Dalay N. (Med. Sci. Monit. 2008)
    258. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study. (PubMed id 18367096)1, 4, 9 Salinas-SA!nchez A.S....Escribano-MartA-nez J. (Urol. Oncol. 2008)
    259. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. (PubMed id 18549475)1, 4, 9 Blons H....Laurent-Puig P. (BMC Med Genomics 2008)
    260. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. (PubMed id 18685109)1, 4, 9 Shlien A....Malkin D. (Proc. Natl. Acad. Sci. U.S.A. 2008)
    261. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. (PubMed id 18288414)1, 4, 9 Boldrini L....Fontanini G. (Oncol. Rep. 2008)
    262. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. (PubMed id 18248785)1, 4, 9 Palmero E.I....Ashton-Prolla P. (Cancer Lett. 2008)
    263. Polymorphisms of COX-2 -765G&gt;C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. (PubMed id 18234542)1, 4, 9 Lin Y.C....Chen C.H. (Oral Oncol. 2008)
    264. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. (PubMed id 18258602)1, 4, 9 Ji X....Li G. (Carcinogenesis 2008)
    265. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. (PubMed id 18640142)1, 4, 9 Chung C.J....Hsueh Y.M. (Toxicol. Appl. Pharmacol. 2008)
    266. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. (PubMed id 18676755)1, 4, 9 Etienne-Grimaldi M.C....Milano G. (Clin. Cancer Res. 2008)
    267. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. (PubMed id 18361427)1, 4, 9 Ye Y....Gu J. (Cancer 2008)
    268. TP53 codon 72 polymorphism in adult soft tissue sarcomas. (PubMed id 19065769)1, 4, 9 Almeida P.S....Saddi V.A. (Genet. Mol. Res. 2008)
    269. The p53 R72P polymorphism does not influence cervical cancer development in a Portuguese population: a study in exfoliated cervical cells. (PubMed id 18205229)1, 4, 9 Oliveira S....Medeiros R. (J. Med. Virol. 2008)
    270. TP53 gene expression, codon 72 polymorphism and human papillomavirus DNA associated with pterygium. (PubMed id 19065760)1, 4, 9 Rodrigues F.W....Moura K.K. (Genet. Mol. Res. 2008)
    271. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. (PubMed id 18313915)1, 4, 9 Phang B.H....Sabapathy K. (Eur. J. Cancer 2008)
    272. P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. (PubMed id 17970074)1, 4, 9 Brant O....Gottschlich S. (Anticancer Res. 2007)
    273. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. (PubMed id 17284368)1, 4, 9 Khadang B....Ghaderi A. (Cancer Genet. Cytogenet. 2007)
    274. p53 codon 72 polymorphism in patients affected with ulcerative colitis. (PubMed id 17671760)1, 4, 9 Vietri M.T....Molinari A.M. (J. Gastroenterol. 2007)
    275. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. (PubMed id 17326708)1, 4, 9 Galipeau P.C....Reid B.J. (PLoS Med. 2007)
    276. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. (PubMed id 18265644)1, 4, 9 Wang J.Y....Lin S.R. (Hepatogastroenterology 2007)
    277. p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. (PubMed id 17492690)1, 4, 9 Perrone F....Pilotti S. (Cancer 2007)
    278. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. (PubMed id 17599946)1, 4, 9 Zhu Z.Z....Zhu G. (Jpn. J. Clin. Oncol. 2007)
    279. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. (PubMed id 17624602)1, 4, 9 Monnerat C....Bressac-de Paillerets B. (Fam. Cancer 2007)
    280. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer. (PubMed id 17403527)1, 4, 9 Bendesky A....Ostrosky-Wegman P. (Mutat. Res. 2007)
    281. Analysis of R213R and 13494 g--&gt;a polymorphisms of the p53 gene in individuals with esophagitis, intestinal metaplasia of the cardia and Barrett's Esophagus compared with a control group. (PubMed id 18923929)1, 4, 9 Pilger D.A....Leistner-Segal S. (Genomic Med 2007)
    282. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. (PubMed id 17223878)1, 4, 9 Stefanaki I....Katsambas A.D. (Br. J. Dermatol. 2007)
    283. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. (PubMed id 17925548)1, 4, 9 Marsh S....Brown R. (J. Clin. Oncol. 2007)
    284. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. (PubMed id 17932356)1, 4, 9 Lind H....Zienolddiny S. (amp 2007)
    285. Telomere length in hepatocellular carcinoma and paired adjacent non-tumor tissues by quantitative PCR. (PubMed id 18058461)1, 4, 9 Zhang Y....Santella R.M. (Cancer Invest. 2007)
    286. Transcriptional functionality of germ line p53 mutants influences cancer phenotype. (PubMed id 17606709)1, 4, 9 Monti P....Fronza G. (Clin. Cancer Res. 2007)
    287. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. (PubMed id 16525684)1, 4, 9 Rogounovitch T.I....Yamashita S. (Oncol. Rep. 2006)
    288. P53 genetic polymorphism of gastric cancer in Korea. (PubMed id 16646561)1, 4, 9 Chung W.C....Chung I.S. (Korean J. Intern. Med. 2006)
    289. [Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer]. (PubMed id 16699611)1, 4, 9 Lima J.M....Forones N.M. (Arq Gastroenterol 2006)
    290. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. (PubMed id 16739124)1, 4, 9 Han J....Hunter D.J. (Mol. Carcinog. 2006)
    291. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. (PubMed id 16609366)1, 4, 9 Wegman P....Wingren S. (Pharmacogenet. Genomics 2006)
    292. Selected risk factors, human papillomavirus infection and the p53 codon 72 polymorphism in patients with squamous intraepithelial lesions in northeastern Thailand. (PubMed id 16629527)1, 4, 9 Settheetham-Ishida W....Ishida T. (Asian Pac. J. Cancer Prev. 2006)
    293. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. (PubMed id 16407418)1, 4, 9 de las PeA+as R....Rosell R. (Ann. Oncol. 2006)
    294. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. (PubMed id 16739339)1, 4, 9 Gadducci A....Cavazzana A.O. (Anticancer Res. 2006)
    295. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. (PubMed id 17409930)1, 4, 9 Zhang W....Siegfried J.M. (J Thorac Oncol 2006)
    296. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. (PubMed id 16524972)1, 4, 9 Iacopetta B....Ishioka C. (Ann. Oncol. 2006)
    297. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. (PubMed id 16174251)1, 4, 9 Saffari B....Press M.F. (Int. J. Gynecol. Cancer 2005)
    298. [Application of oligonucleotide microarray primer extension to detection of p53 single nucleotide polymorphisms]. (PubMed id 16004824)1, 4, 9 Wu Q.H....Zheng W.L. (Ai Zheng 2005)
    299. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. (PubMed id 15899386)1, 4, 9 Santos A.M....Medeiros R. (Cancer Genet. Cytogenet. 2005)
    300. p53 gene mutation and human papillomavirus (HPV) infection in esophageal carcinoma from three different endemic geographic regions of India. (PubMed id 15639342)1, 4, 9 Katiyar S....Das B.C. (Cancer Lett. 2005)
    301. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. (PubMed id 15802278)1, 4, 9 Andersson J....Bergh J. (Ann. Oncol. 2005)
    302. p53 Genotypes and risk of glioma and meningioma. (PubMed id 16172235)1, 4, 9 Malmer B....Henriksson R. (amp 2005)
    303. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. (PubMed id 16172461)1, 4, 9 Russo A....Gebbia N. (J. Clin. Oncol. 2005)
    304. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern Idia. (PubMed id 15981211)1, 4, 9 Mitra S....Roychoudhury S. (Int. J. Cancer 2005)
    305. Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese. (PubMed id 16271069)1, 4, 9 Goan Y.G....Cheng J.T. (Cancer Sci. 2005)
    306. p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. (PubMed id 16129609)1, 4, 9 Kozomara R....MiniA8 V. (J Craniomaxillofac Surg 2005)
    307. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. (PubMed id 16061860)1, 4, 9 HernA!ndez S....Real F.X. (Clin. Cancer Res. 2005)
    308. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. (PubMed id 16030116)1, 4, 9 Wiencke J.K....Wrensch M. (amp 2005)
    309. Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women. (PubMed id 15216398)1, 4, 9 Wu M.T....Wu T.N. (J. Formos. Med. Assoc. 2004)
    310. Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. (PubMed id 15177663)1, 4, 9 Neuhaus T....BrA1ning T. (Toxicol. Lett. 2004)
    311. p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: a cross-sectional study from northeastern Italy. (PubMed id 15140517)1, 4, 9 Comar M....Campello C. (Eur. J. Obstet. Gynecol. Reprod. Biol. 2004)
    312. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms. (PubMed id 15534883)1, 4, 9 Liu G....Christiani D.C. (Cancer 2004)
    313. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. (PubMed id 15573180)1, 4, 9 Mahasneh A.A. and Abdel-Hafiz S.S. (Saudi Med J 2004)
    314. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. (PubMed id 15365822)1, 4, 9 Lung F.W....Chang F.H. (J. Cancer Res. Clin. Oncol. 2004)
    315. p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. (PubMed id 15533911)1, 4, 9 Scheckenbach K....Balz V. (amp 2004)
    316. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. (PubMed id 15099969)1, 4, 9 Roh J.W....Lee H.P. (Gynecol. Oncol. 2004)
    317. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. (PubMed id 14997055)1, 4, 9 Lai H....Lai S. (Breast Cancer Res. Treat. 2004)
    318. [Functional polymorphism of p53 and CCR5 genes in the long-lived of the Siberian region]. (PubMed id 15651660)1, 4, 9 Smetannikova M.A....Voevoda M.I. (Vestn. Akad. Med. Nauk SSSR 2004)
    319. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. (PubMed id 15186775)1, 2, 9 An W.... Roeder R.G. (Cell 2004)
    320. [Correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance]. (PubMed id 16200870)1, 4, 9 Zhou C.Z....Xu J. (Zhonghua Jie He He Hu Xi Za Zhi 2004)
    321. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. (PubMed id 15257943)1, 4, 9 Bergamaschi G....Cazzola M. (Haematologica 2004)
    322. [Association of p53 gene polymorphism with susceptibility to ovarian cancer]. (PubMed id 15634502)1, 4, 9 Kang S....Li Y. (Zhonghua Fu Chan Ke Za Zhi 2004)
    323. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. (PubMed id 14654539)1, 4, 9 Geisler S....nning P.E. (Clin. Cancer Res. 2003)
    324. P53 codon 72 polymorphism in breast cancer. (PubMed id 12684648)1, 4, 9 Buyru N....Dalay N. (Oncol. Rep. 2003)
    325. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. (PubMed id 12724314)1, 2, 9 Wang Y.H.... Lee S.C. (J. Biol. Chem. 2003)
    326. p53 codon 72 polymorphism and risk of cervical cancer. (PubMed id 14513722)1, 4, 9 Ojeda J.M....Rothhammer F. (Biol. Res. 2003)
    327. Haplotype structure of TP53 locus in Indian population and possible association with head and neck cancer. (PubMed id 12556232)1, 4, 9 Mitra S....Roychoudhury S. (Ann. Hum. Genet. 2003)
    328. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. (PubMed id 12550754)1, 4, 9 Vos M....van Helden P.D. (Cancer Genet. Cytogenet. 2003)
    329. Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP. (PubMed id 12376521)1, 4, 9 Qian G.S....Jackson P.E. (amp 2002)
    330. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. (PubMed id 11780126)1, 2, 9 D'Orazi G.... Soddu S. (Nat. Cell Biol. 2002)
    331. TP53 codon 72 polymorphism in oral squamous cell carcinoma. (PubMed id 12530090)1, 4, 9 Drummond S.N....Gomez R.S. (Anticancer Res. 2002)
    332. Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. (PubMed id 12458344)1, 4, 9 Pillai M.R....Herman B. (J. Cancer Res. Clin. Oncol. 2002)
    333. Regulation of p53 activity by its interaction with homeodomain- interacting protein kinase-2. (PubMed id 11740489)1, 2, 9 Hofmann T.G.... Schmitz M.L. (Nat. Cell Biol. 2002)
    334. Waf-1 (p21) and p53 polymorphisms in breast cancer. (PubMed id 11815410)1, 4, 9 Keshava C....Weston A. (amp 2002)
    335. Determination of p53 genotypes in oral cancer patients from India. (PubMed id 11259085)1, 4, 9 Tandle A.T....Saranath D. (Br. J. Cancer 2001)
    336. The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. (PubMed id 11597326)1, 4, 9 Marsh A.... . (Breast Cancer Res. 2001)
    337. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. (PubMed id 11174479)1, 4, 9 Kim J.W....Lee H.P. (Am. J. Obstet. Gynecol. 2001)
    338. p53 amino acids 339-346 represent the minimal p53 repression domain. (PubMed id 11007800)1, 2, 9 Hong T.M.... Wu C.W. (J. Biol. Chem. 2001)
    339. TP53 polymorphism, HPV infection, and risk of cervical cancer. (PubMed id 11535556)1, 4, 9 Klug S.J....MuA+oz N. (amp 2001)
    340. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. (PubMed id 11481490)1, 2, 9 Ribeiro R.C.... Sandrini R. (Proc. Natl. Acad. Sci. U.S.A. 2001)
    341. Absence of germline and somatic p53 alterations in children with sporadic brain tumors. (PubMed id 11519852)1, 4, 9 Portwine C....Malkin D. (J. Neurooncol. 2001)
    342. Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. (PubMed id 11023613)1, 2, 9 Anderson C.W. and Allalunis-Turner M.J. (Radiat. Res. 2000)
    343. Drastic genetic instability of tumors and normal tissues in Turcot syndrome. (PubMed id 9419979)1, 2, 9 Miyaki M.... Utsunomiya J. (Oncogene 1997)
    344. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. (PubMed id 7887414)1, 2, 9 Frebourg T.... Friend S.H. (Am. J. Hum. Genet. 1995)
    345. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. (PubMed id 7878469)1, 2, 9 Jeffrey P.D.... Pavletich N.P. (Science 1995)
    346. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. (PubMed id 8336944)1, 2, 9 Hamelin R.... Thomas G. (Oncogene 1993)
    347. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. (PubMed id 1327751)1, 2, 9 Crook T. and Vousden K.H. (EMBO J. 1992)
    348. Frequent p53 mutations in head and neck cancer. (PubMed id 1394225)1, 2, 9 Somers K.D....Casey G. (Cancer Res. 1992)
    349. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. (PubMed id 1737852)1, 2, 9 Felix C.A.... Minna J.D. (J. Clin. Invest. 1992)
    350. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. (PubMed id 1999338)1, 2, 9 Olschwang S.... Thomas G. (Hum. Genet. 1991)
    351. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. (PubMed id 1849234)1, 2, 9 Hsu I.C.... Harris C.C. (Nature 1991)
    352. Frequent mutation of the p53 gene in human esophageal cancer. (PubMed id 2263646)1, 2, 9 Hollstein M.C.... Harris C.C. (Proc. Natl. Acad. Sci. U.S.A. 1990)
    353. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. (PubMed id 2259385)1, 2, 9 Srivastava S.... Chang E.H. (Nature 1990)
    354. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. (PubMed id 23431171)1, 2 Rokudai S....Prives C. (Proc. Natl. Acad. Sci. U.S.A. 2013)
    355. The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest. (PubMed id 22214662)1, 2 Bennett R.L.... May W.S. Jr. (Cell Cycle 2012)
    356. p53 opens the mitochondrial permeability transition pore to trigger necrosis. (PubMed id 22726440)1, 2 Vaseva A.V....Moll U.M. (Cell 2012)
    357. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. (PubMed id 22864287)1, 2 Cui G.... Mer G. (Nat. Struct. Mol. Biol. 2012)
    358. TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. (PubMed id 21051533)1, 4 Joshi A.M....Yasunami Y. (Jpn. J. Clin. Oncol. 2011)
    359. Promoter methylation of the RGC32 gene in nonsmall cell lung cancer. (PubMed id 20862745)1, 4 Kim D.S....Park J.Y. (Cancer 2011)
    360. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. (PubMed id 21070477)1, 4 Chang Y.L....Lee Y.C. (Cancer Sci. 2011)
    361. No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. (PubMed id 20496166)1, 4 Ma Y....Qin H. (Breast Cancer Res. Treat. 2011)
    362. Mutations of p53 gene in breast cancer in the Egyptian province of Dakahliya. (PubMed id 20015931)1, 4 El-Ghannam D.M....Badrawy T. (J Oncol Pharm Pract 2011)
    363. Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression. (PubMed id 20959462)1, 2 Wu L.... Jain A. (J. Biol. Chem. 2011)
    364. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis. (PubMed id 20861852)1, 4 Jiang D.K....Yu L. (J. Invest. Dermatol. 2011)
    365. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. (PubMed id 21946351)1, 2 Stacey S.N.... Stefansson K. (Nat. Genet. 2011)
    366. Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia. (PubMed id 20232390)1, 4 Shi J.Y....Chen S.J. (Int. J. Cancer 2011)
    367. Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. (PubMed id 20496165)1, 4 Monsees G.M....Han J. (Breast Cancer Res. Treat. 2011)
    368. NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. (PubMed id 21952639)1, 2 Mori T.... Kochi H. (Cell Cycle 2011)
    369. The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. (PubMed id 19523860)1, 4 Santos L.E....Ward L.S. (Urol. Oncol. 2011)
    370. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. (PubMed id 20309940)1, 4 Xu Y....Hu Z. (Int. J. Cancer 2011)
    371. Association of glutathione S-transferase, EPHX, and p53 codon 72 gene polymorphisms with adult acute myeloid leukemia. (PubMed id 20731606)1, 4 Chauhan P.S....Kapur S. (DNA Cell Biol. 2011)
    372. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. (PubMed id 20524403)1, 4 Roh J.W....Kang S.B. (Oncol. Res. 2010)
    373. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. (PubMed id 20875869)1, 4 Xu B....Hua L.X. (Cancer Genet. Cytogenet. 2010)
    374. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. (PubMed id 19885698)1, 4 Makino T....Doki Y. (Ann. Surg. Oncol. 2010)
    375. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. (PubMed id 20234365)1, 4 Evans D.G....Lalloo F. (Br. J. Cancer 2010)
    376. Study of p53 codon 72 polymorphism and codon 249 mutations in Southern India in relation to age, alcohol drinking and smoking habits. (PubMed id 19948747)1, 4 Pandima Devi K....Karutha Pandian S. (amp 2010)
    377. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. (PubMed id 20219101)1, 4 Chua H.W....Seow A. (BMC Cancer 2010)
    378. TP53 gene mutations in prostate cancer progression. (PubMed id 20592345)1, 4 Ecke T.H....Loening S.A. (Anticancer Res. 2010)
    379. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. (PubMed id 20734458)1, 4 Kim H.N....Kim H.J. (Am. J. Hematol. 2010)
    380. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. (PubMed id 20606085)1, 4 Hennessy B.T....Mills G.B. (J. Clin. Oncol. 2010)
    381. Evidence that genetic variants of metabolic detoxication and cell cycle control are not related to gallbladder cancer risk in Chilean women. (PubMed id 20544687)1, 4 Tsuchiya Y....Yamamoto M. (Int. J. Biol. Markers 2010)
    382. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. (PubMed id 20511662)1, 4 Oscier D....Catovsky D. (Haematologica 2010)
    383. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma. (PubMed id 20807096)1, 4 Liu Y.Y....Yang S.J. (amp 2010)
    384. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. (PubMed id 19786980)1, 4 Khrunin A.V....Limborska S. (Pharmacogenomics J. 2010)
    385. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. (PubMed id 20861914)1, 4 Zenz T....Stilgenbauer S. (Leukemia 2010)
    386. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. (PubMed id 20802181)1, 4 Wong K.K....Gershenson D.M. (Am. J. Pathol. 2010)
    387. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. (PubMed id 21060032)1, 4 Pfaff E....Pfister S.M. (J. Clin. Oncol. 2010)
    388. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. (PubMed id 20491880)1, 4 Willander K....Linderholm M. (Eur. J. Haematol. 2010)
    389. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. (PubMed id 20628086)1, 4 Bailey S.D....Anand S. (Diabetes Care 2010)
    390. Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. (PubMed id 21156242)1, 4 Pandith A.A....Siddiqi M. (Cancer Genet. Cytogenet. 2010)
    391. Examination of genetic polymorphisms in newborns for signatures of sex-specific prenatal selection. (PubMed id 20587610)1, 4 Ucisik-Akkaya E....Dorak M.T. (Mol. Hum. Reprod. 2010)
    392. The prevalence of the mutation in codon 249 of the P53 gene in patients with hepatocellular carcinoma (HCC) in Turkey. (PubMed id 20306157)1, 4 Ozdemir F.T....OzdoA9an O. (J Gastrointest Cancer 2010)
    393. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. (PubMed id 20106900)1, 4 Truong T....Hung R.J. (Carcinogenesis 2010)
    394. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. (PubMed id 20673990)1, 2 Huarte M.... Rinn J.L. (Cell 2010)
    395. Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. (PubMed id 20372852)1, 4 Kiyohara C....Nakanishi Y. (Oncol. Rep. 2010)
    396. [Investigation of detoxification polymorphisms genes, methylenetetrahydrofolate-reductase (MTHFR) and P53 in the radiosensitive human cells]. (PubMed id 20464958)1, 4 Shagirova Z.h.M....Zasukhina G.D. (Radiats Biol Radioecol 2010)
    397. Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease. (PubMed id 20110711)1, 4 Zimmer V....Assmann G. (Digestion 2010)
    398. Association of the DSS1 c.143G&gt;A polymorphism with skin squamous cell carcinoma. (PubMed id 20220765)1, 4 Venza M....Teti D. (J. Invest. Dermatol. 2010)
    399. Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis. (PubMed id 19499352)1, 4 Zhang J....Zhang Y.S. (Med. Oncol. 2010)
    400. USP10 regulates p53 localization and stability by deubiquitinating p53. (PubMed id 20096447)1, 2 Yuan J.... Lou Z. (Cell 2010)
    401. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. (PubMed id 20398418)1, 4 Xiao M....Liu Y. (BMC Cancer 2010)
    402. p53 abnormality and tumor invasion in patients with malignant astrocytoma. (PubMed id 21046311)1, 4 Momota H....Shibui S. (Brain Tumor Pathol 2010)
    403. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. (PubMed id 20855462)1, 4 Sun T....Kantoff P.W. (Clin. Cancer Res. 2010)
    404. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. (PubMed id 20660729)1, 2 Burrows A.E.... Elledge S.J. (Proc. Natl. Acad. Sci. U.S.A. 2010)
    405. TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. (PubMed id 20615891)1, 4 Dahabreh I.J....Murray S. (amp 2010)
    406. An intronic variant in the TP53 gene in Serbian women with cervical or ovarian cancer. (PubMed id 20362235)1, 4 Malisic E.J....Radulovic S.S. (Cancer Genet. Cytogenet. 2010)
    407. Specific intronic p53 mutation in esophageal squamous cell carcinoma in Southern Thailand. (PubMed id 21072901)1, 4 Thongsuksai P....Sudhikaran W. (World J. Gastroenterol. 2010)
    408. Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. (PubMed id 20455025)1, 4 Robertson L.B....Houlston R.S. (Fam. Cancer 2010)
    409. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. (PubMed id 20127014)1, 4 Tanuma J....Kitano M. (Oncol. Rep. 2010)
    410. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. (PubMed id 20089604)1, 4 Hu Z....Su L. (Carcinogenesis 2010)
    411. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. (PubMed id 20018398)1, 4 Jin G....Park J.Y. (Lung Cancer 2010)
    412. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. (PubMed id 20233677)1, 4 Trifa F....Mokdad-Gargouri R. (Cancer Epidemiol 2010)
    413. TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. (PubMed id 21061796)1, 4 Bisof V....Rudan P. (Eur. J. Gynaecol. Oncol. 2010)
    414. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. (PubMed id 20173098)1, 2 Fu X.... Wang Y. (Proc. Natl. Acad. Sci. U.S.A. 2010)
    415. G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. (PubMed id 20124405)1, 2 Chen X.... Ma L. (J. Biol. Chem. 2010)
    416. TNF superfamily gene polymorphism as prognostic factor in early breast cancer. (PubMed id 19890662)1, 4 Jung J.H....Park H.Y. (J. Cancer Res. Clin. Oncol. 2010)
    417. Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. (PubMed id 20364130)1, 2 Kitayner M....Shakked Z. (Nat. Struct. Mol. Biol. 2010)
    418. Genetic polymorphism of p53, but not GSTP1, is association with susceptibility to esophageal cancer risk - a meta-analysis. (PubMed id 20827430)1, 4 Zhao Y....Du Y. (Int J Med Sci 2010)
    419. Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. (PubMed id 19657731)1, 4 Hu Z....Su L. (Breast Cancer Res. Treat. 2010)
    420. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. (PubMed id 20501846)1, 4 Mouchawar J....Southey M.C. (Cancer Res. 2010)
    421. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. (PubMed id 20174854)1, 4 Antonelli M....Giangaspero F. (J. Neurooncol. 2010)
    422. Interleukin 10 polymorphisms differentially influence the risk of gastric cancer in East Asians and Caucasians. (PubMed id 20363151)1, 4 Won H.H....Lee K.A. (Cytokine 2010)
    423. Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. (PubMed id 20662834)1, 4 MartA-n-Ezquerra G....Pujol R.M. (Br. J. Dermatol. 2010)
    424. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. (PubMed id 20552631)1, 4 Haferlach C....Haferlach T. (amp 2010)
    425. TP53 mutation profile of esophageal squamous cell carcinomas of patients from Southeastern Brazil. (PubMed id 19944185)1, 4 Rossini A....Ribeiro Pinto L.F. (Mutat. Res. 2010)
    426. Association of polymorphisms of tumor necrosis factor and tumor protein p53 with primary open-angle glaucoma. (PubMed id 20357201)1, 4 Fan B.J....Pang C.P. (amp 2010)
    427. Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women. (PubMed id 20732856)1, 4 Jiang P....Tang J. (Acta Biochim. Biophys. Sin. (Shanghai) 2010)
    428. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. (PubMed id 20731661)1, 4 Kim M....Park J.Y. (Cancer Sci. 2010)
    429. p53 codon 72 polymorphism and risk of cervical carcinoma in Moroccan women. (PubMed id 19771536)1, 4 El khair M.M....El Mzibri M. (Med. Oncol. 2010)
    430. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. (PubMed id 20380571)1, 4 Kara N....Bagci H. (DNA Cell Biol. 2010)
    431. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. (PubMed id 20229506)1, 4 Ahmed A.A....Brenton J.D. (J. Pathol. 2010)
    432. Association of P53 codon 72 polymorphism and ameloblastoma. (PubMed id 20412452)1, 4 Kitkumthorn N....Mutirangura A. (Oral Dis 2010)
    433. Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer. (PubMed id 20730711)1, 4 Li D.B....Xu F. (Genet. Mol. Res. 2010)
    434. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. (PubMed id 20482849)1, 4 Fu Y.P....Prokunina-Olsson L. (Mol. Cancer 2010)
    435. Herpesvirus type 7 infection may play an important role in individuals with a genetic profile of susceptibility to Graves' disease. (PubMed id 19903800)1, 4 Leite J.L....Ward L.S. (Eur. J. Endocrinol. 2010)
    436. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. (PubMed id 20177704)1, 4 Bozhanov S.S....Georgieva E.I. (J. Cancer Res. Clin. Oncol. 2010)
    437. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. (PubMed id 19214744)1, 4 Palanca Suela S....Bolufer Gilabert P. (Breast Cancer Res. Treat. 2010)
    438. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. (PubMed id 20634494)1, 4 LodAc L....Avet-Loiseau H. (Haematologica 2010)
    439. TP53 mutation and survival in chronic lymphocytic leukemia. (PubMed id 20697090)1, 4 Zenz T....Stilgenbauer S. (J. Clin. Oncol. 2010)
    440. Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis--a pilot study. (PubMed id 20532936)1, 4 Moodley D....Chuturgoon A.A. (Clin. Rheumatol. 2010)
    441. Genetic susceptibility to distinct bladder cancer subphenotypes. (PubMed id 19692168)1, 4 Guey L.T....Malats N. (Eur. Urol. 2010)
    442. Dietary folate and vitamin B6 are not associated with p53 mutations in esophageal adenocarcinoma. (PubMed id 20025073)1, 4 Balbuena L. and Casson A.G. (Mol. Carcinog. 2010)
    443. Lifestyle factors and p53 mutation patterns in colorectal cancer patients in the EPIC-Norfolk study. (PubMed id 20228093)1, 4 Park J.Y....Rodwell S.A. (Mutagenesis 2010)
    444. p53 Codon 72 polymorphism is associated with occurrence of cervical carcinoma in the Chinese population. (PubMed id 19576684)1, 4 Ye F....Chen H. (Cancer Lett. 2010)
    445. p53 codon 72 polymorphism and type 1 diabetes mellitus. (PubMed id 20480729)1, 4 Manca Bitti M.L....Gloria-Bottini F. (amp 2010)
    446. The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. (PubMed id 19609560)1, 4 Bauerschlag D.O....Meinhold-Heerlein I. (J. Cancer Res. Clin. Oncol. 2010)
    447. p53 Pro72Arg polymorphism and prostate cancer in men of African descent. (PubMed id 20593380)1, 4 Ricks-Santi L....Dunston G.M. (Prostate 2010)
    448. Can a phenotype for recessive inheritance in breast cancer be defined? (PubMed id 20549370)1, 4 Ellberg C....Olsson H. (Fam. Cancer 2010)
    449. p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma. (PubMed id 20385133)1, 2 Lim S.O.... Jung G. (FEBS Lett. 2010)
    450. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. (PubMed id 20449797)1, 4 Sameer A.S....Siddiqi M.A. (Genet. Mol. Res. 2010)
    451. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. (PubMed id 20308654)1, 4 Tabori U....Malkin D. (J. Clin. Oncol. 2010)
    452. Dermatologic findings in renal transplant recipients: Possible effects of immunosuppression regimen and p53 mutations. (PubMed id 20832539)1, 4 Serdar Z.A....Titiz M.I. (Transplant. Proc. 2010)
    453. A novel functional DEC1 promoter polymorphism -249T&gt;C reduces risk of squamous cell carcinoma of the head and neck. (PubMed id 20935061)1, 4 Huang Y.J....Wei Q. (Carcinogenesis 2010)
    454. Diet, physical activity, and body size associations with rectal tumor mutations and epigenetic changes. (PubMed id 20383576)1, 4 Slattery M.L....Samowitz W. (amp 2010)
    455. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. (PubMed id 19302219)1, 4 Liu G....Christiani D.C. (Dis. Esophagus 2010)
    456. The impact of a high-frequency microsatellite instability phenotype on the tumor location-related genetic differences in colorectal cancer. (PubMed id 20082848)1, 4 Zhao Y....Maehara Y. (Cancer Genet. Cytogenet. 2010)
    457. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation. (PubMed id 20682393)1, 4 Kuo S.J....Liu C.S. (Cancer Genet. Cytogenet. 2010)
    458. p53 Codon 72 polymorphism and gastric cancer risk in a Chinese Han population. (PubMed id 20939739)1, 4 Zhou Y....Wu X. (Genet Test Mol Biomarkers 2010)
    459. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. (PubMed id 20036807)1, 4 Kaneko K....Imawari M. (Front Biosci (Landmark Ed) 2010)
    460. Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. (PubMed id 19950226)1, 4 Kontorovich T....Friedman E. (Int. J. Cancer 2010)
    461. TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South America. (PubMed id 19955396)1, 4 SzymaA8ska K....Brennan P. (Carcinogenesis 2010)
    462. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. (PubMed id 19672706)1, 4 (Breast Cancer Res. Treat. 2010)
    463. Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. (PubMed id 20630574)1, 4 Jiang D.K....Yu L. (Urology 2010)
    464. TP53 genetic polymorphisms and environmental risk factors associated with cervical carcinogenesis in a cohort of Brazilian women with cervical lesions. (PubMed id 20563922)1, 4 Ferreira da Silva I....Koifman S. (J. Toxicol. Environ. Health Part A 2010)
    465. No mutation detected in five hot spot codons of the TP53 gene by restriction site mutation analysis in patients with carcinoma of the tongue. (PubMed id 20306449)1, 4 Vora H.H....Shah P.M. (Int. J. Biol. Markers 2010)
    466. Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. (PubMed id 20225330)1, 4 Li F....Li G. (Cancer 2010)
    467. Latitude may modify the effect of TP53 codon 72 polymorphism on cancer risk. (PubMed id 20564066)1, 4 Sergentanis T.N. and Economopoulos K.P. (Cancer 2010)
    468. Alcohol consumption and rectal tumor mutations and epigenetic changes. (PubMed id 20628283)1, 4 Slattery M.L....Samowitz W. (Dis. Colon Rectum 2010)
    469. Involvement of CYP1A1, GST, 72TP53 polymorphisms in the pathogenesis of thyroid nodules. (PubMed id 21086258)1, 4 Reis A.A....da Cruz A.D. (Genet. Mol. Res. 2010)
    470. A Large-scale genetic association study of esophageal adenocarcinoma risk. (PubMed id 20453000)1, 4 Liu C.Y....Christiani D.C. (Carcinogenesis 2010)
    471. p53 codon 72 polymorphism association with head and neck squamous cell carcinoma. (PubMed id 20658010)1, 4 Mojtahedi Z....Ghaderi A. (Braz J Otorhinolaryngol 2010)
    472. The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. (PubMed id 19184427)1, 4 Kim N....Song I.S. (Dig. Dis. Sci. 2010)
    473. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily. (PubMed id 20130515)1, 4 Agodi A....Travali S. (Int. J. Gynecol. Cancer 2010)
    474. G9a and Glp methylate lysine 373 in the tumor suppressor p53. (PubMed id 20118233)1, 2 Huang J.... Berger S.L. (J. Biol. Chem. 2010)
    475. R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history. (PubMed id 20309662)1, 4 Eren F....Ozer A. (Pathol. Oncol. Res. 2010)
    476. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. (PubMed id 20071787)1, 4 Mojtahedi Z....Ghaderi A. (Indian J Cancer 2010)
    477. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. (PubMed id 20870725)1, 2 West L.E.... Gozani O. (J. Biol. Chem. 2010)
    478. Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival. (PubMed id 19880522)1, 2 Lim S.T.... Schlaepfer D.D. (J. Biol. Chem. 2010)
    479. Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. (PubMed id 19367581)1, 4 So H.C....Sham P.C. (Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010)
    480. Sporadic TP53 transition mutations in chronic cholecystitis are possibly linked to gallbladder carcinogenesis. (PubMed id 21115891)1, 4 Yanagisawa N....Okayasu I. (Anticancer Res. 2010)
    481. Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. (PubMed id 20219685)1, 4 Inkster B....Matthews P.M. (Neuroimage 2010)
    482. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome. (PubMed id 19779722)1, 4 Assmann G....Roemer K. (Rheumatol. Int. 2010)
    483. Pro variant of TP53 Arg72Pro contributes to esophageal squamous cell carcinoma risk: evidence from a meta-analysis. (PubMed id 20389250)1, 4 Wang B....Jin H. (Eur. J. Cancer Prev. 2010)
    484. Betel quid chewing as an environmental risk factor for breast cancer. (PubMed id 20728566)1, 4 Kaushal M....Saxena S. (Mutat. Res. 2010)
    485. Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. (PubMed id 19996201)1, 4 Nemunaitis J....Goodwin W.J. (Clin. Cancer Res. 2009)
    486. Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. (PubMed id 19527492)1, 4 Nielsen M....Morreau H. (BMC Cancer 2009)
    487. Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. (PubMed id 19339270)1, 4 Canova C....Brennan P. (Cancer Res. 2009)
    488. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. (PubMed id 19124506)1, 4 Mavaddat N....Pharoah P.D. (amp 2009)
    489. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. (PubMed id 19170196)1, 4 Shen M....Lan Q. (Environ. Mol. Mutagen. 2009)
    490. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. (PubMed id 19318491)1, 4 Firoz E.F....Polsky D. (Clin. Cancer Res. 2009)
    491. The Pro/Pro genotype of the p53 codon 72 polymorphism modulates PAI-1 plasma levels in ageing. (PubMed id 19523975)1, 4 Testa R....Franceschi C. (Mech. Ageing Dev. 2009)
    492. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. (PubMed id 20021639)1, 4 Schmidt M.K....Nevanlinna H. (Breast Cancer Res. 2009)
    493. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. (PubMed id 19794270)1, 4 Sameer A.S....Siddiqi M.A. (Saudi J Gastroenterol 2009)
    494. Association of genetic polymorphisms, mRNA expression of p53 and p21 with chronic benzene poisoning in a chinese occupational population. (PubMed id 19505915)1, 4 Sun P....Xia Z.L. (amp 2009)
    495. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. (PubMed id 18814047)1, 4 Nan H....Han J. (amp 2009)
    496. Analysis of candidate genes in occurrence and growth of colorectal adenomas. (PubMed id 19888426)1, 4 Olschwang S....Bonaiti-PelliAc C. (J Oncol 2009)
    497. The TP53 Arg72Pro and MDM2 309G&gt;T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (PubMed id 19707196)1, 4 Sinilnikova O.M....Stoppa-Lyonnet D. (Br. J. Cancer 2009)
    498. JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. (PubMed id 19509332)1, 2 Sun L.... Shang Y. (Proc. Natl. Acad. Sci. U.S.A. 2009)
    499. Role of TP53 in the progression of pre-malignant and malignant oral mucosal lesions. A follow-up study of 144 patients. (PubMed id 19473450)1, 4 OgmundsdA^ttir H.M....Holbrook W.P. (amp 2009)
    500. Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. (PubMed id 19129997)1, 4 CA!ceres D.D....IrarrA!zabal C.E. (Lung 2009)
    501. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma. (PubMed id 19286843)1, 4 Akulevich N.M....Yamashita S. (Endocr. Relat. Cancer 2009)
    502. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. (PubMed id 19237633)1, 4 Ogino S....Fuchs C.S. (J. Clin. Oncol. 2009)
    503. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. (PubMed id 19536092)1, 4 Kweekel D.M....Guchelaar H.J. (Br. J. Cancer 2009)
    504. Trim24 targets endogenous p53 for degradation. (PubMed id 19556538)1, 2 Allton K.... Barton M.C. (Proc. Natl. Acad. Sci. U.S.A. 2009)
    505. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. (PubMed id 19224585)1, 4 Polakova V....Vodicka P. (Hum. Mutat. 2009)
    506. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. (PubMed id 19309322)1, 4 Ishikawa Y....Naoe T. (Eur. J. Haematol. 2009)
    507. TP53 codon 72 polymorphism and breast cancer in northern Iran. (PubMed id 19911701)1, 4 Kazemi M....Chakosari R.J. (Oncol. Res. 2009)
    508. Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity. (PubMed id 19773279)1, 4 Hosgood H.D....Lan Q. (Occup Environ Med 2009)
    509. Somatic alterations, metabolizing genes and smoking in rectal cancer. (PubMed id 19358278)1, 4 Curtin K....Slattery M.L. (Int. J. Cancer 2009)
    510. [Evaluation of the p53 Arg72Pro polymorphism as a prognostic factor in severe head injury and the inclusion of this indicator in a predictive model]. (PubMed id 20112543)1, 4 MartA-nez Lucas P....Escribano MartA-nez J. (Rev Esp Anestesiol Reanim 2009)
    511. Genetic mutations associated with cigarette smoking in pancreatic cancer. (PubMed id 19351817)1, 4 Blackford A....Hruban R.H. (Cancer Res. 2009)
    512. Genetic variation in healthy oldest-old. (PubMed id 19680556)1, 4 Halaschek-Wiener J....Brooks-Wilson A.R. (PLoS ONE 2009)
    513. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. (PubMed id 19451596)1, 4 Toffoli G....Serra M. (Clin. Cancer Res. 2009)
    514. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. (PubMed id 19237173)1, 4 Hirata H....Dahiya R. (J. Urol. 2009)
    515. [Mutations of tumor suppressor gemne TP53 in tobacco smoke-associated tumors]. (PubMed id 20301891)1, 4 Szyfter K....JagodziA8ski P. (Prz. Lek. 2009)
    516. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. (PubMed id 19367277)1, 4 Chang-Claude J....Popanda O. (Br. J. Cancer 2009)
    517. Genomic instability and tumor-specific DNA alterations in oral leukoplakias. (PubMed id 19583749)1, 4 TaniA8 N....DimitrijeviA8 B. (Eur. J. Oral Sci. 2009)
    518. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. (PubMed id 19776115)1, 2 Hwang E.S....Huang E.S. (J. Virol. 2009)
    519. A role for the p53 pathway in the pathology of meningiomas with NF2 loss. (PubMed id 18974932)1, 4 Chang Z....Nunes F.P. (J. Neurooncol. 2009)
    520. Plk1-mediated phosphorylation of Topors regulates p53 stability. (PubMed id 19473992)1, 2 Yang X.... Liu X. (J. Biol. Chem. 2009)
    521. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. (PubMed id 19608020)1, 4 Zhuo X.L....Zhang X.Y. (Arch. Med. Res. 2009)
    522. Lack of association between p53 gene polymorphisms and primary open angle glaucoma in the Japanese population. (PubMed id 19471604)1, 4 Mabuchi F....Tsukahara S. (Mol. Vis. 2009)
    523. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. (PubMed id 19366907)1, 4 SzymaA+ska K....Hainaut P. (amp 2009)
    524. PDCD1, CTLA-4 and p53 gene polymorphism and susceptibility to gestational trophoblastic diseases. (PubMed id 19263877)1, 4 Dehaghani A.S....Ghaderi A. (J Reprod Med 2009)
    525. p53 and nasopharyngeal carcinoma: a Malaysian study. (PubMed id 19900105)1, 4 Hoe S.L....Peh S.C. (Pathology 2009)
    526. 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. (PubMed id 19558663)1, 4 Nogueira J.A....Alves V.A. (BMC Cancer 2009)
    527. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. (PubMed id 19623649)1, 4 Yan L....Han B. (Int. J. Cancer 2009)
    528. [Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer]. (PubMed id 19538885)1, 4 Tang J.H....Xu Z.Y. (Zhonghua Zhong Liu Za Zhi 2009)
    529. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. (PubMed id 18487080)1, 4 Huang S.F....Hsieh L.L. (Oral Oncol. 2009)
    530. P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure. (PubMed id 18829023)1, 4 Goodman C....Coulam C.B. (Fertil. Steril. 2009)
    531. The p53 codon 72 single nucleotide polymorphism lacks a significant effect on implantation rate in fresh in vitro fertilization cycles: an analysis of 1,056 patients. (PubMed id 18930193)1, 4 Patounakis G....Frattarelli J.L. (Fertil. Steril. 2009)
    532. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. (PubMed id 19861461)1, 4 Felsberg J....Sabel M.C. (Clin. Cancer Res. 2009)
    533. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. (PubMed id 19276375)1, 4 Schildkraut J.M....Garcia-Closas M. (Cancer Res. 2009)
    534. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. (PubMed id 18830263)1, 4 Wang S.S....Cerhan J.R. (Leukemia 2009)
    535. [TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela]. (PubMed id 19662811)1, 4 CaA+as M....Chiurillo M.A. (Invest Clin 2009)
    536. Association study between P53 and P73 gene polymorphisms and the sporadic late-onset form of Alzheimer's disease. (PubMed id 19657586)1, 4 Scacchi R....Corbo R.M. (J Neural Transm 2009)
    537. PTEN identified as important risk factor of chronic obstructive pulmonary disease. (PubMed id 19625176)1, 4 Hosgood H.D....Lan Q. (Respir Med 2009)
    538. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. (PubMed id 19273710)1, 4 Iacobuzio-Donahue C.A....Laheru D. (J. Clin. Oncol. 2009)
    539. Candidate gene association study of esophageal squamous cell carcinoma in a high-risk region in Iran. (PubMed id 19826048)1, 4 Akbari M.R....Narod S.A. (Cancer Res. 2009)
    540. Association of p53 polymorphism with ICSI/IVF failure and recurrent pregnancy loss. (PubMed id 19432615)1, 4 Firouzabadi R.D....Tabibnejad N. (amp 2009)
    541. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. (PubMed id 18996393)1, 2 Suad O.... Shakked Z. (J. Mol. Biol. 2009)
    542. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. (PubMed id 19704056)1, 4 Ogino S....Fuchs C.S. (J. Clin. Oncol. 2009)
    543. [Analysis of K-ras, BRCA1/2, CHEK2 mutations and microsatellite markers (loss of heterozygosity at 9p, 17p and 18q) in sporadic pancreas adenocarcinomas]. (PubMed id 19548527)1, 4 Amosenko F.A....Kalinin V.N. (Mol. Biol. (Mosk.) 2009)
    544. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. (PubMed id 18758183)1, 4 Tiroch K....Kastrati A. (Cardiology 2009)
    545. Primary open angle glaucoma was not found to be associated with p53 codon 72 polymorphism in a Brazilian cohort. (PubMed id 19291875)1, 4 Silva R.E....Moura K.K. (Genet. Mol. Res. 2009)
    546. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. (PubMed id 18843282)1, 4 Dicker F....Haferlach C. (Leukemia 2009)
    547. Gene mutations in esophageal mucosa of chagas disease patients. (PubMed id 19414370)1, 4 DA Silva Manoel-Caetano F....Silva A.E. (Anticancer Res. 2009)
    548. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. (PubMed id 18468835)1, 4 Mammano E....Nitti D. (Eur J Surg Oncol 2009)
    549. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity. (PubMed id 18978339)1, 4 Lan Q....Rothman N. (Carcinogenesis 2009)
    550. Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients. (PubMed id 19091625)1, 4 Zemleduch T....JagodziA8ski P.P. (Oral Oncol. 2009)
    551. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T&gt;C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. (PubMed id 19219602)1, 4 Kim J.G....Jun S.H. (Cancer Chemother. Pharmacol. 2009)
    552. Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study. (PubMed id 18950845)1, 4 Vega A....Carracedo A. (Gynecol. Oncol. 2009)
    553. Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. (PubMed id 19294769)1, 4 Karim S. and Ali A. (World J. Gastroenterol. 2009)
    554. Polymorphism of tumor protein p53 codon 72 showed no association with oral lichen planus in Shiraz, Iran. (PubMed id 19884837)1, 4 Ghabanchi J....Paydar A.A. (J Craniofac Surg 2009)
    555. Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. (PubMed id 19536170)1, 4 Gao L....Brenner H. (Eur. J. Hum. Genet. 2009)
    556. Lack of correlation between p53 codon 72 polymorphism and anal cancer risk. (PubMed id 19777616)1, 4 Contu S.S....Damin D.C. (World J. Gastroenterol. 2009)
    557. Impact of interaction of polymorphic forms of p53 codon 72 and N-acetylation gene (NAT2) on the risk of lung cancer in the North Indian population. (PubMed id 19558213)1, 4 Sobti R.C....Raimondi S. (DNA Cell Biol. 2009)
    558. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. (PubMed id 19344876)1, 4 Shi H....Lu X. (Am. J. Hum. Genet. 2009)
    559. Long-term survivors of glioblastoma: clinical features and molecular analysis. (PubMed id 19730774)1, 4 Sonoda Y....Tominaga T. (Acta Neurochir (Wien) 2009)
    560. Study of p53 gene mutations and placental expression in recurrent miscarriage cases. (PubMed id 19298746)1, 4 Kaare M....Painter J.N. (Reprod. Biomed. Online 2009)
    561. Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. (PubMed id 19403344)1, 4 Zhou W....d A. (Mol Oncol 2009)
    562. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. (PubMed id 19443408)1, 4 Salek C....Minarik M. (Anticancer Res. 2009)
    563. The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. (PubMed id 19639206)1, 4 LAYng A....Wingren S. (Oncol. Rep. 2009)
    564. Polymorphisms of the ApoE, HSD3B1, IL-1beta and p53 genes are associated with the development of early uremic complications in diabetic patients: results of a DNA resequencing array study. (PubMed id 19148546)1, 4 Szoke D....Tulassay Z. (Int. J. Mol. Med. 2009)
    565. Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. (PubMed id 19237606)1, 4 Michiels S....Benhamou S. (Carcinogenesis 2009)
    566. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. (PubMed id 19147582)1, 4 ManiAc E....Stern M.H. (Cancer Res. 2009)
    567. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. (PubMed id 19822419)1, 4 Stocker G....Keller G. (Eur. J. Cancer 2009)
    568. [Genetic polymorphism in patients with colorectal and with head and neck cancer]. (PubMed id 19643719)1, 4 Csejtei A....Kiss I. (Orv Hetil 2009)
    569. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. (PubMed id 19690970)1, 4 Chen J....Frazier M.L. (amp 2009)
    570. p53 Mutations in carcinoma of the esophagus and gastroesophageal junction. (PubMed id 19160092)1, 4 Sengpiel C....Homann N. (Cancer Invest. 2009)
    571. A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. (PubMed id 19789190)1, 4 Young R.P....Gamble G.D. (Postgrad Med J 2009)
    572. Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. (PubMed id 19963114)1, 4 Klinchid J....Cressey R. (Cancer Genet. Cytogenet. 2009)
    573. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. (PubMed id 18596741)1, 4 Bowen D....Linch D.C. (Leukemia 2009)
    574. Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. (PubMed id 19773383)1, 4 Grochola L.F....Bond G.L. (Clin. Cancer Res. 2009)
    575. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. (PubMed id 19597886)1, 4 Yashiro M....Hirakawa K. (Ann. Surg. Oncol. 2009)
    576. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. (PubMed id 19773259)1, 4 Silva F.P....Giphart-Gassler M. (Haematologica 2009)
    577. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. (PubMed id 19885596)1, 4 HenrA-quez-HernA!ndez L.A....FernA!ndez PAcrez L. (Oncol. Rep. 2009)
    578. Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults. (PubMed id 19074170)1, 4 Onel K.B....Onel K. (Lupus 2009)
    579. Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. (PubMed id 18415014)1, 4 LubiA8ski J....Scott R. (Breast Cancer Res. Treat. 2009)
    580. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study. (PubMed id 19772793)1, 4 Assmann G....Melchers I. (Clin. Exp. Rheumatol. 2009)
    581. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. (PubMed id 19116388)1, 4 Vineis P....Matullo G. (J. Natl. Cancer Inst. 2009)
    582. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. (PubMed id 19046801)1, 4 Hosny G....Hainaut P. (Cancer Lett. 2009)
    583. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. (PubMed id 19336552)1, 4 Morton L.M....Hartge P. (amp 2009)
    584. Analysis of p53 codon 72 gene polymorphism in Brazilian patients with endometriosis. (PubMed id 19551637)1, 4 Ribeiro JA_nior C.L....Moura K.K. (Genet. Mol. Res. 2009)
    585. p53 mutation is rare in oral mucosa brushings from patients previously treated for a head and neck squamous cell carcinoma. (PubMed id 19027352)1, 4 Acha-Sagredo A....Aguirre J.M. (Oral Oncol. 2009)
    586. Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. (PubMed id 19787241)1, 4 Hrstka R....Vojtesek B. (Oncol. Rep. 2009)
    587. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. (PubMed id 19573080)1, 4 Liang X.S....Goldin L.R. (Br. J. Haematol. 2009)
    588. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. (PubMed id 20040103)1, 4 Lung F.W....Tzeng D.S. (BMC Med. Genet. 2009)
    589. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. (PubMed id 19542078)1, 4 Marcel V....Achatz M.I. (J. Med. Genet. 2009)
    590. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary. (PubMed id 19643813)1, 4 Anna L....Schoket B. (Mutagenesis 2009)
    591. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. (PubMed id 19956635)1, 4 Holmes M.V....Casas J.P. (PLoS ONE 2009)
    592. P53 Arg72Pro polymorphism in gastric cancer patients. (PubMed id 19543839)1, 4 Gomes de Souza L....Manoukian Forones N. (J Gastrointest Cancer 2009)
    593. P53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population. (PubMed id 18269649)1, 4 Shao Y....Zhang S. (Dis. Esophagus 2008)
    594. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. (PubMed id 18314181)1, 4 Shah C.A....Swisher E.M. (Gynecol. Oncol. 2008)
    595. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. (PubMed id 18665932)1, 4 Kim N....Song I.S. (Helicobacter 2008)
    596. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. (PubMed id 17719241)1, 4 Singh V....Singh M.P. (Ann Epidemiol 2008)
    597. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. (PubMed id 18650397)1, 2 Boeckler F.M.... Fersht A.R. (Proc. Natl. Acad. Sci. U.S.A. 2008)
    598. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. (PubMed id 17967874)1, 2 Shouse G.P.... Liu X. (Mol. Cell. Biol. 2008)
    599. Detection of p53 codon 249 mutation in Nigerian patients with hepatocellular carcinoma using a novel evaluation of cell-free DNA. (PubMed id 19034233)1, 4 Igetei R....Gormally E. (Ann Hepatol 2008)
    600. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. (PubMed id 19094228)1, 4 Tapper W....Eccles D. (Breast Cancer Res. 2008)
    601. Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population. (PubMed id 18798306)1, 4 Pangilinan F....Brody L.C. (Am. J. Med. Genet. A 2008)
    602. Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma. (PubMed id 19115684)1, 4 de Carvalho C.R....Ribalta J.C. (Eur. J. Gynaecol. Oncol. 2008)
    603. [Correlation analysis between clinical phenotypes of keloids and polymorphism of p53 gene codon 72]. (PubMed id 19137883)1, 4 Liu Y....Liu H. (Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2008)
    604. Association of p53 codon 72 polymorphism with endometriosis. (PubMed id 17931634)1, 4 Ammendola M....Bottini E. (Fertil. Steril. 2008)
    605. Nuclear FAK promotes cell proliferation and survival through FERM- enhanced p53 degradation. (PubMed id 18206965)1, 2 Lim S.T.... Ilic D. (Mol. Cell 2008)
    606. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. (PubMed id 18262501)1, 4 Idbaih A....Delattre J.Y. (Brain Res. 2008)
    607. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. (PubMed id 18618574)1, 4 Han J.Y....Lee J.S. (Cancer 2008)
    608. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. (PubMed id 18854777)1, 4 Wu X....Spitz M.R. (Pharmacogenet. Genomics 2008)
    609. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. (PubMed id 18676680)1, 4 Hosgood H.D....Lan Q. (Carcinogenesis 2008)
    610. Arsenic-induced health effects and genetic damage in keratotic individuals: involvement of p53 arginine variant and chromosomal aberrations in arsenic susceptibility. (PubMed id 18249029)1, 4 De Chaudhuri S....Giri A.K. (Mutat. Res. 2008)
    611. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. (PubMed id 18585004)1, 2 Xie P....He F. (Cell. Signal. 2008)
    612. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. (PubMed id 18823025)1, 4 Ye Y....Wu X. (Cancer 2008)
    613. Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. (PubMed id 17683074)1, 4 Van Emburgh B.O....Miller M.S. (Mol. Carcinog. 2008)
    614. p53 Codon 72 polymorphism and the risk of esophageal squamous cell carcinoma. (PubMed id 17918207)1, 4 Yang W....Ke Y. (Mol. Carcinog. 2008)
    615. Reprimo 824 G&gt;C and p53R2 4696 C&gt;G single nucleotide polymorphisms and colorectal cancer: a case-control disease association study. (PubMed id 18197409)1, 4 Beasley W.D....Parry J.M. (Int J Colorectal Dis 2008)
    616. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. (PubMed id 18455581)1, 4 Kandioler D....Klepetko W. (J. Thorac. Cardiovasc. Surg. 2008)
    617. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. (PubMed id 18355840)1, 4 Hirata H....Dahiya R. (J. Urol. 2008)
    618. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. (PubMed id 18511570)1, 4 Bougeard G....FrAcbourg T. (J. Med. Genet. 2008)
    619. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. (PubMed id 18393224)1, 4 Pinto G.R....Casartelli C. (Genet. Mol. Res. 2008)
    620. Etiologic value of p53 mutation spectra and differences with histology in lung cancers. (PubMed id 18271927)1, 4 Shimmyo T....Tsuchiya E. (Cancer Sci. 2008)
    621. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. (PubMed id 18498133)1, 4 Nordgard S.H....Kristensen V.N. (Int. J. Cancer 2008)
    622. Evaluation of the polymorphisms in the exons 2 to 4 of the TP53 in cervical carcinoma patients from a Brazilian population. (PubMed id 18954551)1, 4 Fernandes T.A....Meissner R.V. (Cell. Mol. Biol. (Noisy-le-grand) 2008)
    623. Detection of HPV-DNA, p53 alterations, and methylation in penile squamous cell carcinoma in Japanese men. (PubMed id 18705766)1, 4 Yanagawa N....Motoyama T. (Pathol. Int. 2008)
    624. Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China. (PubMed id 18714189)1, 4 Zheng X.Z....Jiang J.F. (Eur. J. Cancer Prev. 2008)
    625. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. (PubMed id 19064572)1, 4 Palmieri R.T.... . (amp 2008)
    626. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. (PubMed id 18230179)1, 4 Costa S....Schmitt F. (BMC Cancer 2008)
    627. DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. (PubMed id 18641418)1, 4 CapellA! G....GonzA!lez C.A. (Int J Epidemiol 2008)
    628. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. (PubMed id 18725978)1, 4 Chrisanthar R....nning P.E. (PLoS ONE 2008)
    629. Association between copper excess, zinc deficiency, and TP53 mutations in esophageal squamous cell carcinoma from Kashmir Valley, India--a high risk area. (PubMed id 18791921)1, 4 Dar N.A....Shah A. (Nutr Cancer 2008)
    630. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. (PubMed id 18528419)1, 4 Haferlach C....Haferlach T. (Leukemia 2008)
    631. [Polymorphism of gene p53 and apoptosis in patients with malignant lung disease--our observation]. (PubMed id 19097418)1, 4 Sauka C....JanA-k M. (Klin Onkol 2008)
    632. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. (PubMed id 19506726)1, 4 Gianfagna F....Boccia S. (Curr. Genomics 2008)
    633. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. (PubMed id 18281248)1, 4 Lum S.S....Sabapathy K. (Carcinogenesis 2008)
    634. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. (PubMed id 18583979)1, 4 Allen N.C....Bertram L. (Nat. Genet. 2008)
    635. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. (PubMed id 19074885)1, 4 Enjuanes A....Campo E. (Cancer Res. 2008)
    636. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. (PubMed id 18068527)1, 4 Lima-Ramos V....Reis R.M. (Cancer Genet. Cytogenet. 2008)
    637. Genetic and epigenetic alterations of familial pancreatic cancers. (PubMed id 19064568)1, 4 Brune K....Goggins M. (amp 2008)
    638. P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. (PubMed id 18507052)1, 4 Dakouras A....Karakitsos P. (Anticancer Res. 2008)
    639. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. (PubMed id 18381604)1, 4 Khan S.A....Paty P.B. (J Surg Oncol 2008)
    640. Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function after kidney transplantation. (PubMed id 18640487)1, 4 Israni A.K....Feldman H.I. (Am. J. Kidney Dis. 2008)
    641. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. (PubMed id 18426989)1, 4 Ellis N.A....Onel K. (Blood 2008)
    642. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. (PubMed id 18336951)1, 4 FernA!ndez-Rubio A....TardA^n A. (Lung Cancer 2008)
    643. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. (PubMed id 18715757)1, 4 Shi J....Liu C. (Schizophr. Res. 2008)
    644. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. (PubMed id 19092295)1, 4 Siraj A.K....Al-Kuraya K. (J. Endocrinol. Invest. 2008)
    645. Role of DNA repair systems in malignant tumor development in the elderly. (PubMed id 18713157)1, 4 Arai T....Tanaka N. (amp 2008)
    646. International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. (PubMed id 18990748)1, 4 Hung R.J....Brennan P. (amp 2008)
    647. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. (PubMed id 18259947)1, 4 Boldrini L....Fontanini G. (Cancer Invest. 2008)
    648. K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients. (PubMed id 18957720)1, 4 Strazisar M....Glavac D. (Dis. Markers 2008)
    649. Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma. (PubMed id 18280645)1, 4 Liu Z.M....Peng T. (Cancer Lett. 2008)
    650. Genetic polymorphisms associated with cigarette smoking and the risk of Graves' disease. (PubMed id 17980001)1, 4 Bufalo N.E....Ward L.S. (Clin. Endocrinol. (Oxf) 2008)
    651. Genome wide identification of recessive cancer genes by combinatorial mutation analysis. (PubMed id 18846217)1, 4 Volinia S....Croce C.M. (PLoS ONE 2008)
    652. Effect of genetic predisposition on the risk of gallbladder cancer in Hungary. (PubMed id 18990008)1, 4 Kimura A....Nakamura K. (Asian Pac. J. Cancer Prev. 2008)
    653. Statistical methods for detecting genetic interactions: a head and neck squamous-cell cancer study. (PubMed id 18569579)1, 4 Ickstadt K....Harth V. (J. Toxicol. Environ. Health Part A 2008)
    654. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. (PubMed id 18181044)1, 4 Sreeja L....Ankathil R. (Cancer Invest. 2008)
    655. Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. (PubMed id 18513854)1, 4 Tornesello M.L....Buonaguro F.M. (Cancer Lett. 2008)
    656. Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. (PubMed id 18453682)1, 2 Tu C.... Ji X. (Acta Crystallogr. D 2008)
    657. Study of p53 codon 72 polymorphism in patients with breast cancer. (PubMed id 18714570)1, 4 Vieira J.O....Gebrim L.H. (Eur. J. Gynaecol. Oncol. 2008)
    658. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. (PubMed id 18390844)1, 4 Yoon Y.J....Han K.H. (Carcinogenesis 2008)
    659. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. (PubMed id 17960397)1, 4 GrA1nhage F....Lammert F. (Int J Colorectal Dis 2008)
    660. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. (PubMed id 18628487)1, 4 O'Shea D....Fitzgibbon J. (Blood 2008)
    661. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population]. (PubMed id 18953830)1, 4 Liu J.N....Wen T. (Zhonghua Zhong Liu Za Zhi 2008)
    662. The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis. (PubMed id 18799058)1, 4 Assmann G....Voswinkel J. (Clin. Exp. Rheumatol. 2008)
    663. Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. (PubMed id 17624591)1, 4 Gaudet M.M....Santella R.M. (Breast Cancer Res. Treat. 2008)
    664. H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression. (PubMed id 18240345)1, 4 Lima V.P....Rabenhorst S.H. (World J. Gastroenterol. 2008)
    665. Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. (PubMed id 19018238)1, 4 TabarAcs-Seisdedos R....MartA-nez S. (Psychiatr. Genet. 2008)
    666. Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. (PubMed id 18280004)1, 4 Honma H.N....Zambon L. (Lung Cancer 2008)
    667. COX2 and p53 risk-alleles coexist in COPD. (PubMed id 18692035)1, 4 Arif E....Pasha M.A. ( international journal of clinical chemistry 2008)
    668. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. (PubMed id 18640791)1, 4 De Vecchi G....Peterlongo P. (Cancer Detect. Prev. 2008)
    669. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. (PubMed id 18630481)1, 4 Csejtei A....Kiss I. (Anticancer Res. 2008)
    670. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. (PubMed id 19046423)1, 4 AssumpAsALo J.G....Yunes J.A. (BMC Cancer 2008)
    671. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. (PubMed id 18459109)1, 4 Kibel A.S....Suarez B.K. (Prostate 2008)
    672. TP53 mutations in breast cancer: association with ductal histology and early relapse of disease. (PubMed id 18949740)1, 4 Brankovic-Magic M.V....Radulovic S.S. (Int. J. Biol. Markers 2008)
    673. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. (PubMed id 18332046)1, 4 Woelfelschneider A....Schmezer P. (Carcinogenesis 2008)
    674. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. (PubMed id 18058229)1, 4 Rajkumar T....Nancy N.K. (Breast Cancer Res. Treat. 2008)
    675. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. (PubMed id 18689542)1, 4 Zenz T....Stilgenbauer S. (Blood 2008)
    676. Polymorphism of p53 gene codon 72 in Kuwaiti with coronary artery disease and diabetes. (PubMed id 16797751)1, 4 Alkhalaf M....Abdella N. (Int. J. Cardiol. 2007)
    677. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. (PubMed id 17909070)1, 4 Schmidt M.K....Van't Veer L.J. (Cancer Res. 2007)
    678. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. (PubMed id 17719541)1, 2 Das S....Lee S.W. (Cell 2007)
    679. TP53 mutation in prostate needle biopsies--comparison with patients follow-up. (PubMed id 18225585)1, 4 Ecke T.H....Miller K. (Anticancer Res. 2007)
    680. p53 Codon 72 polymorphism, loss of heterozygosity and high-risk human papillomavirus infection in a low-incidence German esophageal squamous cell carcinoma patient cohort. (PubMed id 17390072)1, 4 Pantelis A....Stoehr R. (Oncol. Rep. 2007)
    681. This article was published online in error and has been removed by the publisher. (PubMed id 17409195)1, 4 (Hum. Mol. Genet. 2007)
    682. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. (PubMed id 18024870)1, 4 Tsao M.S....Shepherd F.A. (J. Clin. Oncol. 2007)
    683. PRAK is essential for ras-induced senescence and tumor suppression. (PubMed id 17254968)1, 2 Sun P.... Han J. (Cell 2007)
    684. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients. (PubMed id 17400332)1, 4 Matakidou A....Houlston R.S. (Lung Cancer 2007)
    685. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. (PubMed id 17591690)1, 2 Lee J.-H.... Kim K.-T. (J. Cell Sci. 2007)
    686. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. (PubMed id 17854663)1, 4 Idbaih A....Delattre J.Y. (Cancer Genet. Cytogenet. 2007)
    687. [Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma]. (PubMed id 17927872)1, 4 Cao Y.Y....Zhang J.H. (Ai Zheng 2007)
    688. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. (PubMed id 17786186)1, 4 Holtkamp N....von Deimling A. (Neoplasia 2007)
    689. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. (PubMed id 18094376)1, 4 Poeta M.L....Koch W.M. (N. Engl. J. Med. 2007)
    690. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. (PubMed id 17535973)1, 4 A9rsted D.D....Nordestgaard B.G. (J. Exp. Med. 2007)
    691. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. (PubMed id 17306604)1, 4 Kuroda Y....Katoh T. (Oral Oncol. 2007)
    692. The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies. (PubMed id 17387621)1, 4 Cox D.G....De Vivo I. (amp 2007)
    693. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage- induced dephosphorylation of p53 at Thr55. (PubMed id 17245430)1, 2 Li H.H.... Liu X. (EMBO J. 2007)
    694. p53 is regulated by the lysine demethylase LSD1. (PubMed id 17805299)1, 2 Huang J.... Berger S.L. (Nature 2007)
    695. Prognostic significance of TP53 mutations in oral squamous cell carcinoma with human papilloma virus infection. (PubMed id 18161655)1, 4 Kozomara R.J....Magic Z.M. (Int. J. Biol. Markers 2007)
    696. GSTM1 and codon 72 P53 polymorphism in multiple myeloma. (PubMed id 17653713)1, 4 Ortega M.M....Lima C.S. (Ann. Hematol. 2007)
    697. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. (PubMed id 17537232)1, 4 Toyama T....Fujii Y. (Breast Cancer Res. 2007)
    698. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. (PubMed id 17171684)1, 4 Galic V....Swisher E.M. (amp 2007)
    699. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. (PubMed id 17638920)1, 4 Yang M....Lin D. (Carcinogenesis 2007)
    700. Modulation of p53 function by SET8-mediated methylation at lysine 382. (PubMed id 17707234)1, 2 Shi X.... Gozani O. (Mol. Cell 2007)
    701. [Association of polymorphous markers Pro72Arg and C(-594)CC OF TP53 gene with diabetic polyneuropathy in patients with type 1 diabetes mellitus living in Moscow]. (PubMed id 18318116)1, 4 Spitsina E.V....Nosikov V.V. (Mol. Biol. (Mosk.) 2007)
    702. 172G&gt;T variant in the 5' untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. (PubMed id 17118968)1, 4 Lu J....Wei Q. (Carcinogenesis 2007)
    703. Detection of oncogenic viruses SV40, BKV, JCV, HCMV, HPV and p53 codon 72 polymorphism in lung carcinoma. (PubMed id 17400331)1, 4 Giuliani L....Ciotti M. (Lung Cancer 2007)
    704. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours. (PubMed id 17727479)1, 4 Ryu M.H....Lee J.S. (Histopathology 2007)
    705. Association of Trp53 polymorphic variants at codon 72 with nonsyndromic mental retardation. (PubMed id 17597242)1, 4 Saccucci P....Curatolo P. (Neurosci. Res. 2007)
    706. Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. (PubMed id 17683073)1, 4 Garcia-Closas M....Chanock S. (Int. J. Cancer 2007)
    707. TP53 codon 72 polymorphism as a risk factor for cardiovascular disease in a Brazilian population. (PubMed id 17934643)1, 4 Smith M.A....PayALo S.L. (Braz. J. Med. Biol. Res. 2007)
    708. Lack of association between polymorphisms in p53 gene and spermatogenetic failure in a Chinese population. (PubMed id 18076421)1, 4 Lu N.X....Wang X.R. (Andrologia 2007)
    709. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. (PubMed id 17059853)1, 4 Popanda O....Schmezer P. (Lung Cancer 2007)
    710. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. (PubMed id 17170702)1, 2 Yamasaki S.... Nakajima T. (EMBO J. 2007)
    711. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. (PubMed id 17301252)1, 4 Mechanic L.E....Harris C.C. (amp 2007)
    712. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. (PubMed id 17449902)1, 4 Sprague B.L....Egan K.M. (Carcinogenesis 2007)
    713. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. (PubMed id 17908995)1, 4 Wang W....Wu X. (Clin. Cancer Res. 2007)
    714. The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients. (PubMed id 17631738)1, 4 Macchioni P....Salvarani C. (Clin. Exp. Rheumatol. 2007)
    715. [TP53 gene polymorphisms and colorectal cancer risk in Chinese population]. (PubMed id 17785079)1, 4 Jia H.R....Zhu G.S. (Zhonghua Yi Xue Za Zhi 2007)
    716. Effects of arsenic exposure and genetic polymorphisms of p53, glutathione S-transferase M1, T1, and P1 on the risk of carotid atherosclerosis in Taiwan. (PubMed id 16973168)1, 4 Wang Y.H....Chen C.J. (Atherosclerosis 2007)
    717. MDM2 SNP309 T&gt;G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. (PubMed id 17096342)1, 4 Talseth B.A....Scott R.J. (Int. J. Cancer 2007)
    718. Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India. (PubMed id 17696741)1, 4 Samson M....Rajkumar T. (Asian Pac. J. Cancer Prev. 2007)
    719. Four novel single nucleotide polymorphisms within the promoter region of p53 gene and their associations with uterine leiomyoma. (PubMed id 17186536)1, 4 Hsieh Y.Y....Lin C.S. (Mol. Reprod. Dev. 2007)
    720. Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes. (PubMed id 17350822)1, 4 Yano M....Asahara T. (Eur. J. Cancer 2007)
    721. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. (PubMed id 17531965)1, 4 Tsuchiya Y....Yamamoto M. (Clin. Biochem. 2007)
    722. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. (PubMed id 17121812)1, 2 Yang W....El-Deiry W.S. (J. Biol. Chem. 2007)
    723. TP53 codon 72 polymorphism in 12 populations of insular Southeast Asia and Oceania. (PubMed id 17607506)1, 4 Kashima T....Ishida T. (J. Hum. Genet. 2007)
    724. p53 genotypes and haplotypes associated with risk of breast cancer. (PubMed id 17574348)1, 4 Buyru N....Dalay N. (Cancer Detect. Prev. 2007)
    725. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. (PubMed id 17319790)1, 4 FranekovA! M....Racay P. (Neoplasma 2007)
    726. The notch regulator MAML1 interacts with p53 and functions as a coactivator. (PubMed id 17317671)1, 2 Zhao Y.... Band V. (J. Biol. Chem. 2007)
    727. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. (PubMed id 17684142)1, 4 Rajaraman P....Inskip P.D. (amp 2007)
    728. Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis. (PubMed id 16988840)1, 4 Xu J.X....Aozasa K. (J. Cancer Res. Clin. Oncol. 2007)
    729. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. (PubMed id 17634560)1, 4 Chen K....Wei Q. (Clin. Cancer Res. 2007)
    730. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. (PubMed id 17785557)1, 4 Hirata H....Dahiya R. (Clin. Cancer Res. 2007)
    731. The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. (PubMed id 17224235)1, 4 KrA1ger S....Schackert H.K. (Cancer Lett. 2007)
    732. Arg72Pro p53 polymorphism in Italian women: no association with endometriosis. (PubMed id 17412337)1, 4 Vietri M.T....Cobellis L. (Fertil. Steril. 2007)
    733. Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. (PubMed id 18022393)1, 2 Arai S.... Kurokawa R. (FEBS Lett. 2007)
    734. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency. (PubMed id 17504512)1, 4 Govan V.A....Williamson A.L. (Int. J. Immunogenet. 2007)
    735. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. (PubMed id 17981213)1, 4 Lahiri O....Howell M. (Cancer Genet. Cytogenet. 2007)
    736. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. (PubMed id 17349958)1, 2 Taira N.... Yoshida K. (Mol. Cell 2007)
    737. Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. (PubMed id 17767549)1, 4 Bhattacharya P. and Sengupta S. (Tissue Antigens 2007)
    738. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. (PubMed id 17108107)1, 2 Zeng P.Y. and Berger S.L. (Cancer Res. 2006)
    739. P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. (PubMed id 16111803)1, 4 Sul J....Zhang Z.F. (Cancer Lett. 2006)
    740. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. (PubMed id 16507123)1, 4 Butt C....Rahman P. (amp 2006)
    741. The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections. (PubMed id 17094395)1, 4 Ciotti M....Favalli C. (Anticancer Res. 2006)
    742. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. (PubMed id 16377624)1, 2 Yoshida K.... Miki Y. (J. Biol. Chem. 2006)
    743. p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. (PubMed id 17007666)1, 4 Kay C....Coulam C.B. (Reprod. Biomed. Online 2006)
    744. Study of a functional polymorphism in the p53 gene in systemic lupus erythematosus: lack of replication in a Spanish population. (PubMed id 17120592)1, 4 SA!nchez E....MartA-n J. (Lupus 2006)
    745. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. (PubMed id 16402859)1, 2 Hu M.... Shi Y. (PLoS Biol. 2006)
    746. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. (PubMed id 17018785)1, 4 (J. Natl. Cancer Inst. 2006)
    747. Association of the PIG3 promoter polymorphism with invasive bladder cancer in a Japanese population. (PubMed id 16418181)1, 4 Ito M....Ogawa O. (Jpn. J. Clin. Oncol. 2006)
    748. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. (PubMed id 16864176)1, 4 Kyndi M....Overgaard J. (Acta Oncol 2006)
    749. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. (PubMed id 16542834)1, 4 Santos A.M....Medeiros R. (Eur. J. Cancer 2006)
    750. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. (PubMed id 17113725)1, 4 Damin A.P....Alexandre C.O. (Cancer Detect. Prev. 2006)
    751. Repression of p53 activity by Smyd2-mediated methylation. (PubMed id 17108971)1, 2 Huang J.... Berger S.L. (Nature 2006)
    752. Structural basis for the methylation site specificity of SET7/9. (PubMed id 16415881)1, 2 Couture J.-F.... Trievel R.C. (Nat. Struct. Mol. Biol. 2006)
    753. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. (PubMed id 16704422)1, 2 Blanco S.... Lazo P.A. (FEBS J. 2006)
    754. Polymorphisms at exon 4 of p53 and the susceptibility to herpesvirus types 6 and 1 infection in renal transplant recipients. (PubMed id 16918534)1, 4 Leite J.L....Ward L.S. (Transpl. Int. 2006)
    755. Role of p53 codon 72 polymorphism in recurrent pregnancy loss. (PubMed id 16569330)1, 4 Coulam C.B....Jeyendran R.S. (Reprod. Biomed. Online 2006)
    756. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. (PubMed id 16458962)1, 4 Kochethu G....Pratt G. (Leuk. Res. 2006)
    757. Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India. (PubMed id 16930632)1, 4 De Chaudhuri S....Roychoudhury S. (Mutat. Res. 2006)
    758. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. (PubMed id 16492918)1, 4 Cai L....Zhang Z.F. (amp 2006)
    759. Germline p53 single-base changes associated with Balkan endemic nephropathy. (PubMed id 16487937)1, 4 Krasteva M.E. and Georgieva E.I. (Biochem. Biophys. Res. Commun. 2006)
    760. Molecular recognition of p53 and MDM2 by USP7/HAUSP. (PubMed id 16474402)1, 2 Sheng Y....Frappier L. (Nat. Struct. Mol. Biol. 2006)
    761. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. (PubMed id 16912209)1, 4 Hung R.J....Brennan P. (Cancer Res. 2006)
    762. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. (PubMed id 16625286)1, 4 QuiA+ones L.A....CA!ceres D.D. (Asian J. Androl. 2006)
    763. Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome. (PubMed id 16631474)1, 4 Jekic B....Bunjevacki V. (Cancer Genet. Cytogenet. 2006)
    764. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. (PubMed id 16318864)1, 4 Lee J.M....Lee Y.C. (Mutat. Res. 2006)
    765. Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. (PubMed id 16835507)1, 4 Sousa H....Medeiros R. (Eur. J. Cancer Prev. 2006)
    766. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. (PubMed id 16465622)1, 4 Wu X....Spitz M.R. (Am. J. Hum. Genet. 2006)
    767. Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon. (PubMed id 16376338)1, 2 Gu Y.-M.... Lee K.-Y. (FEBS Lett. 2006)
    768. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. (PubMed id 16788846)1, 4 Morari E.C....Ward L.S. (J. Cancer Res. Clin. Oncol. 2006)
    769. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. (PubMed id 16489069)1, 4 Olivier M....rresen-Dale A.L. (Clin. Cancer Res. 2006)
    770. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. (PubMed id 16353134)1, 4 Talseth B.A....Scott R.J. (Int. J. Cancer 2006)
    771. No evidence for association of the TP53 12139 and the BAX-248 polymorphisms with endemic pemphigus foliaceus (fogo selvagem). (PubMed id 16611260)1, 4 KAPhler K.F. and Petzl-Erler M.L. (Int. J. Immunogenet. 2006)
    772. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish &quot;MALOVA&quot; ovarian cancer study. (PubMed id 16183105)1, 4 HA...gdall C.K. (Gynecol. Oncol. 2006)
    773. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. (PubMed id 16691626)1, 4 Gu J....Berman D.M. (Cancer 2006)
    774. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. (PubMed id 16721787)1, 4 Koushik A....Hunter D.J. (Int. J. Cancer 2006)
    775. Critical role for Daxx in regulating Mdm2. (PubMed id 16845383)1, 2 Tang J.... Yang X. (Nat. Cell Biol. 2006)
    776. p53 Mutation analysis in breast tumors by a DNA microarray method. (PubMed id 16434591)1, 4 Tennis M....Freudenheim J.L. (amp 2006)
    777. Association of p53 codon 72 polymorphism with risk of hypopharyngeal squamous cell carcinoma in Taiwan. (PubMed id 16477330)1, 4 Twu C.W....Lin J.C. (J. Formos. Med. Assoc. 2006)
    778. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. (PubMed id 16786124)1, 4 Ignaszak-Szczepaniak M....Slomski R. (Oncol. Rep. 2006)
    779. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. (PubMed id 16258005)1, 4 Bougeard G....Frebourg T. (J. Med. Genet. 2006)
    780. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. (PubMed id 16331344)1, 4 Tan X.L....Chang-Claude J. (Breast Cancer Res. Treat. 2006)
    781. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. (PubMed id 15979781)1, 4 Zhu Z.Z....Zhu G.S. (Cancer Lett. 2005)
    782. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. (PubMed id 15991278)1, 4 Nan H.M....Kim H. (World J. Gastroenterol. 2005)
    783. TP53 gene mutation, an unfavorable prognostic factor for malignant lymphomas in autoimmune diseases. (PubMed id 16131817)1, 4 Hoshida Y....Aozasa K. (Oncology 2005)
    784. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. (PubMed id 15633234)1, 4 Zhu Z.Z....Wu M.C. (World J. Gastroenterol. 2005)
    785. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. (PubMed id 16230424)1, 4 Hong Y....Lin D. (Cancer Res. 2005)
    786. Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury. (PubMed id 16007417)1, 4 MartA-nez-Lucas P....GarcA-a-Olmo D. (Intensive Care Med 2005)
    787. Recurrent pregnancy failure is associated with a polymorphism in the p53 tumour suppressor gene. (PubMed id 15608028)1, 4 Pietrowski D....Tempfer C. (Hum. Reprod. 2005)
    788. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. (PubMed id 15734961)1, 4 Kuang S.Y....Groopman J.D. (amp 2005)
    789. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. (PubMed id 15960923)1, 4 Soto MartA-nez J.L....LA^pez-Nevot M.A. (amp 2005)
    790. NIR is a novel INHAT repressor that modulates the transcriptional activity of p53. (PubMed id 16322561)1, 2 Hublitz P.... Schule R. (Genes Dev. 2005)
    791. p53 isoforms can regulate p53 transcriptional activity. (PubMed id 16131611)1, 2 Bourdon J.C.... Lane D.P. (Genes Dev. 2005)
    792. The functional p53 codon 72 polymorphism is associated with systemic lupus erythematosus. (PubMed id 16302680)1, 4 Lee Y.H....Song G.G. (Lupus 2005)
    793. [Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer]. (PubMed id 16989164)1, 4 Szymanowska A....Jassem J. (Pneumonol Alergol Pol 2005)
    794. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. (PubMed id 15837541)1, 4 Kalemi T.G....Kotsis A. (Cancer Lett. 2005)
    795. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. (PubMed id 15583690)1, 4 Hsieh L.L....Cheng A.J. (Br. J. Cancer 2005)
    796. Genetic variants of TP53 and EPHX1 in Leber's hereditary optic neuropathy and their relationship to age at onset. (PubMed id 15838728)1, 4 Ishikawa K....Mashima Y. (Jpn. J. Ophthalmol. 2005)
    797. Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. (PubMed id 15855171)1, 2 Golubovskaya V.M.... Cance W.G. (J. Biol. Chem. 2005)
    798. Human papillomavirus infection and P53 codon 72 genotypes in a Hispanic population at high-risk for cervical cancer. (PubMed id 16121365)1, 4 Haws A.L....Tyring S.K. (J. Med. Virol. 2005)
    799. Environmental exposure and p53 mutations in esophageal cancer patients in areas of low and high incidence of esophageal cancer in China. (PubMed id 16272802)1, 4 Sakaguchi S....Nakajima T. (Tohoku J. Exp. Med. 2005)
    800. Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis. (PubMed id 15721419)1, 4 Ueda M....Ueki M. (Gynecol. Oncol. 2005)
    801. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. (PubMed id 16243804)1, 4 Xu Y....Xie Y. (Clin. Cancer Res. 2005)
    802. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma. (PubMed id 16009172)1, 4 Denschlag D....Pietrowski D. (Fertil. Steril. 2005)
    803. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. (PubMed id 16122882)1, 4 Koushik A....Franco E.L. (Cancer Detect. Prev. 2005)
    804. The R72P P53 mutation is associated with familial breast cancer in Jewish women. (PubMed id 15756275)1, 4 Ohayon T....Friedman E. (Br. J. Cancer 2005)
    805. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. (PubMed id 16077965)1, 4 Catalano T....Battista P. (Oncol. Rep. 2005)
    806. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. (PubMed id 16014569)1, 4 Austen B....Stankovic T. (Blood 2005)
    807. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. (PubMed id 15609317)1, 4 Sakiyama T....Yokota J. (Int. J. Cancer 2005)
    808. Effect of p53 codon 72 polymorphism on p53 protein expression in pterygium. (PubMed id 15670080)1, 4 Tsai Y.Y....Chau P.S. (amp 2005)
    809. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. (PubMed id 16289503)1, 4 Tornesello M.L....Buonaguro F.M. (Cancer Detect. Prev. 2005)
    810. TP53-binding protein variants and breast cancer risk: a case-control study. (PubMed id 15987456)1, 4 Frank B....Burwinkel B. (Breast Cancer Res. 2005)
    811. Candidate genes associated with ageing and life expectancy in the Jerusalem longitudinal study. (PubMed id 15621215)1, 4 Stessman J....Ebstein R.P. (Mech. Ageing Dev. 2005)
    812. Genotype phenotype correlations in Israeli colorectal cancer patients. (PubMed id 15523694)1, 4 Starinsky S....Friedman E. (Int. J. Cancer 2005)
    813. [p53 gene intron 7 polymorphism and its association with oral neoplasms]. (PubMed id 16255923)1, 4 Li Y.Q....Wu T.S. (Zhonghua Kou Qiang Yi Xue Za Zhi 2005)
    814. Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. (PubMed id 16103461)1, 4 Turner P.C....Wild C.P. (amp 2005)
    815. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33- phosphorylated form binds and stabilizes serine 46-phosphorylated p53. (PubMed id 16219768)1, 2 Chang N.-S.... Hong Q. (J. Biol. Chem. 2005)
    816. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. (PubMed id 15623478)1, 4 Mitra S....Roychoudhury S. (J. Clin. Pathol. 2005)
    817. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. (PubMed id 16033823)1, 4 Tommiska J....Nevanlinna H. (Clin. Cancer Res. 2005)
    818. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. (PubMed id 15958551)1, 4 Le Calvez F....Hainaut P. (Cancer Res. 2005)
    819. Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control and family studies. (PubMed id 16039051)1, 4 Ni X....Kennedy J.L. (Neurosci. Lett. 2005)
    820. [p53 gene codon 72 polymorphism and susceptibility to keloid]. (PubMed id 16128105)1, 4 Zhuo Y....Zhao Y.Z. (Zhonghua Zheng Xing Wai Ke Za Zhi 2005)
    821. Mutation scanning of the p53 tumor suppressor gene in renal and liver transplant patients in Hungary. (PubMed id 15848594)1, 4 Sarvary E....JA!ray J. (Transplant. Proc. 2005)
    822. [Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population]. (PubMed id 16331559)1, 4 Zhu Z.Z....Wu M.C. (Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005)
    823. [Investigation of p53 polymorphism for genetic predisposition of keloid and hypertrophic scar]. (PubMed id 15844595)1, 4 Wang C.M....Nakazawa N. (Zhonghua Zheng Xing Wai Ke Za Zhi 2005)
    824. Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. (PubMed id 15701641)1, 2 Jalota-Badhwar A....Chattopadhyay S. (J. Biol. Chem. 2005)
    825. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). (PubMed id 16199549)1, 4 KrA1ger S....Schackert H.K. (J. Med. Genet. 2005)
    826. [p53 gene codon 72 polymorphism and susceptibility to keloid in Chinese population]. (PubMed id 15704837)1, 4 Zhuo Y....Zhao Y. (Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2005)
    827. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. (PubMed id 15723718)1, 4 Niwa Y....Hamajima N. (Cancer Lett. 2005)
    828. Lack of association of p53 polymorphisms and haplotypes in high and normal tension open angle glaucoma. (PubMed id 16140998)1, 4 Dimasi D.P....Craig J.E. (J. Med. Genet. 2005)
    829. [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population]. (PubMed id 15774209)1, 4 Zhu Z.Z....Wu M.C. (Zhonghua Yi Xue Za Zhi 2005)
    830. Screening of TP53 mutations by DHPLC and sequencing in brain tumours from patients with an occupational exposure to pesticides or organic solvents. (PubMed id 16105905)1, 4 Loyant V....Gauduchon P. (Mutagenesis 2005)
    831. Polymorphism at codon 72 of the p53 gene is not associated with endometriosis in a Japanese population. (PubMed id 15120697)1, 4 Omori S....Maruo T. (J. Soc. Gynecol. Investig. 2004)
    832. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). (PubMed id 15489334)1, 2 Gerhard D.S.... Malek J. (Genome Res. 2004)
    833. Tumor suppressor gene TP53 is genetically associated with schizophrenia in the Chinese population. (PubMed id 15450681)1, 4 Yang Y....He L. (Neurosci. Lett. 2004)
    834. Regulation of human p53 activity and cell localization by alternative splicing. (PubMed id 15340061)1, 2 Ghosh A.... Matlashewski G. (Mol. Cell. Biol. 2004)
    835. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. (PubMed id 14702041)1, 2 Katayama H.... Sen S. (Nat. Genet. 2004)
    836. Regulation of p53 activity through lysine methylation. (PubMed id 15525938)1, 2 Chuikov S....Reinberg D. (Nature 2004)
    837. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. (PubMed id 15183536)1, 4 Settheetham-Ishida W....Ishida T. (Cancer Lett. 2004)
    838. Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits. (PubMed id 15158001)1, 4 Papiol S....FaA+anA!s L. (Neurosci. Lett. 2004)
    839. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. (PubMed id 14744727)1, 4 Koushik A....Franco E.L. (amp 2004)
    840. TP53 haplotype-based analysis and incidence of post-angioplasty restenosis. (PubMed id 14740296)1, 4 Zee R.Y....Lindpaintner K. (Hum. Genet. 2004)
    841. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. (PubMed id 15036662)1, 4 Wu M.T....Wu D.C. (Cancer Lett. 2004)
    842. [Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study]. (PubMed id 15555357)1, 4 Wang X.L....Xu S.Q. (Zhonghua Liu Xing Bing Xue Za Zhi 2004)
    843. p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. (PubMed id 15334668)1, 4 Lu X.M....Wen H. (World J. Gastroenterol. 2004)
    844. Polymorphisms of DNA repair genes and risk of glioma. (PubMed id 15313891)1, 4 Wang L.E....Wei Q. (Cancer Res. 2004)
    845. Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. (PubMed id 14734461)1, 4 Zhang Z.W....Holly J. (Clin. Cancer Res. 2004)
    846. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. (PubMed id 15291355)1, 4 Hishida A....Hamajima N. (amp 2004)
    847. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. (PubMed id 15183535)1, 4 Noma C....Noguchi S. (Cancer Lett. 2004)
    848. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. (PubMed id 14534297)1, 2 Joerger A.C.... Fersht A.R. (J. Biol. Chem. 2004)
    849. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. (PubMed id 15053879)1, 2 Li H.-H.... Liu X. (Mol. Cell 2004)
    850. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. (PubMed id 15145278)1, 4 Jee S.H....Ji S.S. (Int J Gynaecol Obstet 2004)
    851. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. (PubMed id 15138483)1, 4 Menzel H.J....Kraft H.G. (Br. J. Cancer 2004)
    852. Connection between p53 gene Bam HI RFLP polymorphism with the volume of brain infarction in patients with carotid atherothrombotic ischemic stroke. (PubMed id 15272143)1, 4 Skvortsova V.I....Limborska S.A. (Restor. Neurol. Neurosci. 2004)
    853. The Ankrd2 protein, a link between the sarcomere and the nucleus in skeletal muscle. (PubMed id 15136035)1, 2 Kojic S....Faulkner G. (J. Mol. Biol. 2004)
    854. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. (PubMed id 14647431)1, 4 Gemignani F....Canzian F. (Oncogene 2004)
    855. The spectrum of mutations in TP53 in laryngeal cancer patients from a high-incidence population shows similarities to many of the known mutational hotspots. (PubMed id 12935924)1, 4 Barnard D....Victor T.C. (Cancer Genet. Cytogenet. 2003)
    856. Is p53 intronic variant G13964C associated with predisposition to cancer? (PubMed id 14617836)1, 4 Fiszer-Maliszewska A.8....Nowakowska B. (J. Appl. Genet. 2003)
    857. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. (PubMed id 14634508)1, 4 Huang X.E....Tajima K. (Breast Cancer 2003)
    858. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. (PubMed id 12851404)1, 2 Tomasini R.... Dusetti N.J. (J. Biol. Chem. 2003)
    859. An association study of the codon 72 polymorphism in the pro-apoptotic gene p53 and Alzheimer's disease. (PubMed id 12648751)1, 4 Rosenmann H....Abramsky O. (Neurosci. Lett. 2003)
    860. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. (PubMed id 12750254)1, 2 Shiseki M....Harris C.C. (Cancer Res. 2003)
    861. Evidence against involvement of p53 polymorphism in breast cancer predisposition. (PubMed id 12471629)1, 4 Suspitsin E.N....Imyanitov E.N. (Int. J. Cancer 2003)
    862. Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. (PubMed id 14644340)1, 4 de Araujo Souza P.S. and Villa L.L. (Mutat. Res. 2003)
    863. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. (PubMed id 12917199)1, 4 Medina P.P....Sanchez-Cespedes M. (amp 2003)
    864. The p53 codon 72 genotypes in HPV infection and cervical disease. (PubMed id 12818446)1, 4 Abba M.C....Golijow C.D. (Eur. J. Obstet. Gynecol. Reprod. Biol. 2003)
    865. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. (PubMed id 12840112)1, 4 Matakidou A....Houlston R.S. (Mutagenesis 2003)
    866. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. (PubMed id 12796380)1, 4 Zhang Z.W....Holly J. (Clin. Cancer Res. 2003)
    867. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. (PubMed id 12875622)1, 4 Hiraki A....Tajima K. (Asian Pac. J. Cancer Prev. 2003)
    868. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). (PubMed id 12883749)1, 4 Xing D....Lin D. (Oncol. Rep. 2003)
    869. p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. (PubMed id 12820398)1, 4 Cenci M....Vecchione A. (Anticancer Res. 2003)
    870. Analysis of polymorphic patterns in candidate genes in Israeli patients with prostate cancer. (PubMed id 14719475)1, 4 Figer A....Friedman E. (Isr. Med. Assoc. J. 2003)
    871. Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). (PubMed id 12702766)1, 2 Kondo S.... Thukral S.K. (Proc. Natl. Acad. Sci. U.S.A. 2003)
    872. P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. (PubMed id 12911720)1, 4 Pegoraro R.J....Moodley J. (Int. J. Gynecol. Cancer 2003)
    873. [Risk factors for cervico-uterine cancer associated to HPV: p53 codon 72 polymorphism in women attending hospital care]. (PubMed id 12708345)1, 4 Sifuentes Alvarez A. and Reyes Romero M. (Ginecol Obstet Mex 2003)
    874. Polymorphism of codon 72 of p53 and environmental factors in the development of cervical cancer. (PubMed id 12527466)1, 4 Jee S.H....Park J.S. (Int J Gynaecol Obstet 2003)
    875. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. (PubMed id 15033824)1, 4 Mabrouk I....Gargouri A. (Ann. N. Y. Acad. Sci. 2003)
    876. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. (PubMed id 14675203)1, 4 Shen H....Wei Q. (J. Invest. Dermatol. 2003)
    877. Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China. (PubMed id 12670525)1, 4 Hu N....Taylor P.R. (Cancer Detect. Prev. 2003)
    878. Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. (PubMed id 12944468)1, 2 O'Keefe K.... Zhang Y. (Mol. Cell. Biol. 2003)
    879. [Development of chronic obstructive pulmonary disease correlates with mini- and microsatellite locus instability]. (PubMed id 12838617)1, 4 Chizhikov V.V....Zborovskaia I.B. (Genetika 2003)
    880. [Association between Bam HI RFLP p53 gene polymorphism and brain infarction volume in patients with atherothrombotic ischemic stroke]. (PubMed id 12830514)1, 4 Skvortsova V.I....Platonova I.A. (Zh Nevrol Psikhiatr Im S S Korsakova 2003)
    881. The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. (PubMed id 12893432)1, 4 Tiwawech D....Ishida T. (Cancer Lett. 2003)
    882. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. (PubMed id 12582031)1, 4 Su L....Christiani D.C. (amp 2003)
    883. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. (PubMed id 11927843)1, 4 Wang-Gohrke S....Chang-Claude J. (Pharmacogenetics 2002)
    884. Effect of germ-line genetic variation on breast cancer survival in a population-based study. (PubMed id 12036913)1, 4 Goode E.L....Pharoah P.P. (Cancer Res. 2002)
    885. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. (PubMed id 12019159)1, 4 Miller D.P....Christiani D.C. (Cancer Res. 2002)
    886. [Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico]. (PubMed id 12221910)1, 4 SuA!rez-RincA^n A.E....SA!nchez-Corona J. (Ginecol Obstet Mex 2002)
    887. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. (PubMed id 12434294)1, 4 Papadakis E.D....Spandidos D.A. (Br. J. Cancer 2002)
    888. Polymorphisms of CYP1a1, CYP2e1, GSTM1, GSTT1, and TP53 genes in Amerindians. (PubMed id 12365037)1, 4 Gaspar P.A....Weimer T.A. (Am. J. Phys. Anthropol. 2002)
    889. The p53Pro72Arg polymorphism is associated with albuminuria among aboriginal Australians. (PubMed id 11856771)1, 4 McDonald S.P....Wang X.L. (J. Am. Soc. Nephrol. 2002)
    890. Genotype frequencies of 50 polymorphisms for 241 Japanese non-cancer patients. (PubMed id 12164325)1, 4 Hamajima N....Tajima K. (J Epidemiol 2002)
    891. Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. (PubMed id 12071291)1, 4 Biros E....Sulla I. (Physiol Res 2002)
    892. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. (PubMed id 12065086)1, 4 Shen H....Wei Q. (Cancer Lett. 2002)
    893. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. (PubMed id 12168882)1, 4 HA...Kjaer S.K. (Anticancer Res. 2002)
    894. Distributions of p53 codon 72 polymorphism in primary open angle glaucoma. (PubMed id 12084746)1, 4 Lin H.J....Tsai S.W. (Br J Ophthalmol 2002)
    895. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. (PubMed id 11925430)1, 2 Kim E.-J.... Um S.-J. (J. Biol. Chem. 2002)
    896. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. (PubMed id 12115545)1, 4 Hiyama T....Chayama K. (Int. J. Cancer 2002)
    897. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. (PubMed id 12164929)1, 4 McGregor J.M....Crook T. (J. Invest. Dermatol. 2002)